1
|
Andronescu LR, Richard SA, Scher AI, Lindholm DA, Mende K, Ganesan A, Huprikar N, Lalani T, Smith A, Mody RM, Jones MU, Bazan SE, Colombo RE, Colombo CJ, Ewers E, Larson DT, Maves RC, Berjohn CM, Maldonado CJ, English C, Sanchez Edwards M, Rozman JS, Rusiecki J, Byrne C, Simons MP, Tribble D, Burgess TH, Pollett SD, Agan BK. SARS-CoV-2 infection is associated with self-reported post-acute neuropsychological symptoms within six months of follow-up. PLoS One 2024; 19:e0297481. [PMID: 38626117 PMCID: PMC11020833 DOI: 10.1371/journal.pone.0297481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Accepted: 01/02/2024] [Indexed: 04/18/2024] Open
Abstract
BACKGROUND Chronic neuropsychological sequelae following SARS-CoV-2 infection, including depression, anxiety, fatigue, and general cognitive difficulties, are a major public health concern. Given the potential impact of long-term neuropsychological impairment, it is important to characterize the frequency and predictors of this post-infection phenotype. METHODS The Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) study is a longitudinal study assessing the impact of SARS-CoV-2 infection in U.S. Military Healthcare System (MHS) beneficiaries, i.e. those eligible for care in the MHS including active duty servicemembers, dependents, and retirees. Four broad areas of neuropsychological symptoms were assessed cross-sectionally among subjects 1-6 months post-infection/enrollment, including: depression (Patient Health Questionnaire-9), anxiety (General Anxiety Disorder-7), fatigue (PROMIS® Fatigue 7a), and cognitive function (PROMIS® Cognitive Function 8a and PROMIS® Cognitive Function abilities 8a). Multivariable Poisson regression models compared participants with and without SARS-CoV-2 infection history on these measures, adjusting for sex, ethnicity, active-duty status, age, and months post-first positive or enrollment of questionnaire completion (MPFP/E); models for fatigue and cognitive function were also adjusted for depression and anxiety scores. RESULTS The study population included 2383 participants who completed all five instruments within six MPFP/E, of whom 687 (28.8%) had at least one positive SARS-CoV-2 test. Compared to those who had never tested positive for SARS-CoV-2, the positive group was more likely to meet instrument-based criteria for depression (15.4% vs 10.3%, p<0.001), fatigue (20.1% vs 8.0%, p<0.001), impaired cognitive function (15.7% vs 8.6%, p<0.001), and impaired cognitive function abilities (24.3% vs 16.3%, p<0.001). In multivariable models, SARS-CoV-2 positive participants, assessed at an average of 2.7 months after infection, had increased risk of moderate to severe depression (RR: 1.44, 95% CI 1.12-1.84), fatigue (RR: 2.07, 95% CI 1.62-2.65), impaired cognitive function (RR: 1.64, 95% CI 1.27-2.11), and impaired cognitive function abilities (RR: 1.41, 95% CI 1.15-1.71); MPFP/E was not significant. CONCLUSIONS Participants with a history of SARS-CoV-2 infection were up to twice as likely to report cognitive impairment and fatigue as the group without prior SARS-CoV-2 infection. These findings underscore the continued importance of preventing SARS-CoV-2 infection and while time since infection/enrollment was not significant through 6 months of follow-up, this highlights the need for additional research into the long-term impacts of COVID-19 to mitigate and reverse these neuropsychological outcomes.
Collapse
Affiliation(s)
- Liana R. Andronescu
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America
| | - Stephanie A. Richard
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America
| | - Ann I. Scher
- Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
| | - David A. Lindholm
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Brooke Army Medical Center, San Antonio, TX, United States of America
| | - Katrin Mende
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America
- Brooke Army Medical Center, San Antonio, TX, United States of America
| | - Anuradha Ganesan
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America
- Walter Reed National Military Medical Center, Bethesda, MD, United States of America
| | - Nikhil Huprikar
- Walter Reed National Military Medical Center, Bethesda, MD, United States of America
| | - Tahaniyat Lalani
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America
- Naval Medical Center Portsmouth, Portsmouth, VA, United States of America
| | - Alfred Smith
- Naval Medical Center Portsmouth, Portsmouth, VA, United States of America
| | - Rupal M. Mody
- William Beaumont Army Medical Center, El Paso, TX, United States of America
| | - Milissa U. Jones
- Tripler Army Medical Center, Honolulu, HI, United States of America
| | - Samantha E. Bazan
- Carl R. Darnall Army Medical Center, Fort Hood, TX, United States of America
| | - Rhonda E. Colombo
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Madigan Army Medical Center, Tacoma, WA, United States of America
| | - Christopher J. Colombo
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Madigan Army Medical Center, Tacoma, WA, United States of America
| | - Evan Ewers
- Fort Belvoir Community Hospital, Fort Belvoir, VA, United States of America
| | - Derek T. Larson
- Fort Belvoir Community Hospital, Fort Belvoir, VA, United States of America
- Naval Medical Center San Diego, San Diego, CA, United States of America
| | - Ryan C. Maves
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Naval Medical Center San Diego, San Diego, CA, United States of America
| | - Catherine M. Berjohn
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Naval Medical Center San Diego, San Diego, CA, United States of America
| | | | - Caroline English
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America
| | - Margaret Sanchez Edwards
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America
| | - Julia S. Rozman
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America
| | - Jennifer Rusiecki
- Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
| | - Celia Byrne
- Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
| | - Mark P. Simons
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
| | - David Tribble
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
| | - Timothy H. Burgess
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
| | - Simon D. Pollett
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America
| | - Brian K. Agan
- Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America
| |
Collapse
|
2
|
Ashina H, Diener HC, Tassorelli C, Scher AI, Lipton RB, Pozo-Rosich P, Sinclair AJ, Chong CD, Finkel AG, Ashina M, Schwedt TJ, Dodick DW, Terwindt GM. Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injury. Cephalalgia 2024; 44:3331024241234068. [PMID: 38518177 DOI: 10.1177/03331024241234068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/24/2024]
Abstract
BACKGROUND Persistent headache attributed to traumatic injury to the head is divided into two subtypes, one attributed to moderate or severe traumatic injury and another attributed to mild traumatic injury (i.e., concussion). The latter is much more prevalent, in part because more than 90% of cases with traumatic brain injury are classified as mild. The pathophysiology of persistent post-traumatic headache is poorly understood and the underlying mechanisms are likely multifactorial. There is currently no approved treatment specifically for persistent post-traumatic headache, and management strategies rely on medications used for migraine or tension-type headache. Therefore, high-quality trials are urgently needed to support clinical decision-making and optimize management strategies. International guidelines can facilitate appropriate trial design and ensure the acquisition of high-quality data evaluating the efficacy, tolerability, and safety of available and novel pharmacological therapies for the preventive treatment of persistent post-traumatic headache. METHODS The development of this guideline was based on a literature review of available studies in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, along with a review of previously published guidelines for controlled trials of preventive treatment for episodic and chronic migraine. The identified literature was critically appraised, and due to the scarcity of scientific evidence, recommendations were primarily based on the consensus of experts in the field. OBJECTIVE To provide guidelines for designing state-of-the-art controlled clinical trials aimed at evaluating the effectiveness of preventive treatments for persistent post-traumatic headache attributed to mild traumatic brain injury.
Collapse
Affiliation(s)
- Håkan Ashina
- Harvard Medical School, MA, USA
- Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
- Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
- Department of Brain and Spinal Cord Injury, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Hans-Christoph Diener
- Institute for Medical Informatics, Biometry and Epidemiology, Medical Faculty, University Duisburg-Essen, Essen, Germany
| | - Cristina Tassorelli
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
- Headache Science & Neurorehabilitation Centre, IRCCS C Mondino Foundation, Pavia, Italy
| | - Ann I Scher
- Department of Preventive Medicine and Biostatistics, Uniformed Services University, Bethesda, MD, USA
| | - Richard B Lipton
- Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
- Montefiore Headache Center, Bronx, NY, USA
| | - Patricia Pozo-Rosich
- Headache Unit, Neurology Department, Vall d'Hebron University Hospital; and Headache Research Group, Vall d'Hebron Institute of Research, Barcelona, Spain
- Headache Research Group, Vall d'Hebron Institute of Research, Departament de Medicina, Universitat Autonoma de Barcelona, Barcelona, Spain
| | - Alexandra J Sinclair
- Translational Brain Science, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
| | | | | | - Messoud Ashina
- Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Todd J Schwedt
- Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
| | - David W Dodick
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
| | - Gisela M Terwindt
- Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands
| |
Collapse
|
3
|
Scher AI, Chai X, Johnson KW. Author Response to Comment on "Plasma calcitonin gene-related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion". Headache 2024; 64:121. [PMID: 38238971 DOI: 10.1111/head.14665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2023] [Accepted: 12/13/2023] [Indexed: 01/23/2024]
Affiliation(s)
- Ann I Scher
- Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Xiyun Chai
- Precision Medicine Neuroscience, AbbVie, North Chicago, Illinois, USA
| | - Kirk W Johnson
- Pain Research, Eli Lilly and Company, Indianapolis, Indiana, USA
| |
Collapse
|
4
|
Richard SA, Scher AI, Rusiecki J, Byrne C, Berjohn CM, Fries AC, Lalani T, Smith AG, Mody RM, Ganesan A, Huprikar N, Colombo RE, Colombo CJ, Schofield C, Lindholm DA, Mende K, Morris MJ, Jones MU, Flanagan R, Larson DT, Ewers EC, Bazan SE, Saunders D, Maves RC, Livezey J, Maldonado CJ, Edwards MS, Rozman JS, O’Connell RJ, Simons MP, Tribble DR, Agan BK, Burgess TH, Pollett SD. Decreased Self-reported Physical Fitness Following SARS-CoV-2 Infection and the Impact of Vaccine Boosters in a Cohort Study. Open Forum Infect Dis 2023; 10:ofad579. [PMID: 38130596 PMCID: PMC10733205 DOI: 10.1093/ofid/ofad579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Accepted: 11/15/2023] [Indexed: 12/23/2023] Open
Abstract
Background The long-term effects of coronavirus disease 2019 (COVID-19) on physical fitness are unclear, and the impact of vaccination on that relationship is uncertain. Methods We compared survey responses in a 1-year study of US military service members with (n = 1923) and without (n = 1591) a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We fit Poisson regression models to estimate the association between history of SARS-CoV-2 infection and fitness impairment, adjusting for time since infection, demographics, and baseline health. Results The participants in this analysis were primarily young adults aged 18-39 years (75%), and 71.5% were male. Participants with a history of SARS-CoV-2 infection were more likely to report difficulty exercising (38.7% vs 18.4%; P < .01), difficulty performing daily activities (30.4% vs 12.7%; P < .01), and decreased fitness test (FT) scores (42.7% vs 26.2%; P < .01) than those without a history of infection. SARS-CoV-2-infected participants were at higher risk of these outcomes after adjusting for other factors (unvaccinated: exercising: adjusted risk ratio [aRR], 3.99; 95% CI, 3.36-4.73; activities: aRR, 5.02; 95% CI, 4.09-6.16; FT affected: aRR, 2.55; 95% CI, 2.19-2.98). Among SARS-CoV-2-positive participants, full vaccination before infection was associated with a lower risk of post-COVID-19 fitness impairment (fully vaccinated: exercise: aRR, 0.81; 95% CI, 0.70-0.95; activities: aRR, 0.76; 95% CI, 0.64-0.91; FT: aRR, 0.87; 95% CI, 0.76-1.00; boosted: exercise: aRR, 0.62; 95% CI, 0.51-0.74; activities: aRR, 0.52; 95% CI, 0.41-0.65; FT: aRR, 0.59; 95% CI, 0.49-0.70). Conclusions In this study of generally young, healthy military service members, SARS-CoV-2 infection was associated with lower self-reported fitness and exercise capacity; vaccination and boosting were associated with lower risk of self-reported fitness loss.
Collapse
Affiliation(s)
- Stephanie A Richard
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA
| | - Ann I Scher
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Jennifer Rusiecki
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Celia Byrne
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Catherine M Berjohn
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Naval Medical Center San Diego, San Diego, California, USA
| | - Anthony C Fries
- US Air Force School of Aerospace Medicine, Wright-Patterson, Ohio, USA
| | - Tahaniyat Lalani
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA
- Naval Medical Center Portsmouth, Portsmouth, Virginia, USA
| | - Alfred G Smith
- Naval Medical Center Portsmouth, Portsmouth, Virginia, USA
| | - Rupal M Mody
- William Beaumont Army Medical Center, El Paso, Texas, USA
| | - Anuradha Ganesan
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA
- Walter Reed National Military Medical Center, Bethesda, Maryland, USA
| | - Nikhil Huprikar
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Walter Reed National Military Medical Center, Bethesda, Maryland, USA
| | - Rhonda E Colombo
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Madigan Army Medical Center, Joint Base Lewis McChord, Washington, USA
| | - Christopher J Colombo
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Madigan Army Medical Center, Joint Base Lewis McChord, Washington, USA
| | | | - David A Lindholm
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Brooke Army Medical Center, Joint Base San Antonio-Fort Sam Houston, Texas, USA
| | - Katrin Mende
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA
- Brooke Army Medical Center, Joint Base San Antonio-Fort Sam Houston, Texas, USA
| | - Michael J Morris
- Brooke Army Medical Center, Joint Base San Antonio-Fort Sam Houston, Texas, USA
| | - Milissa U Jones
- Department of Pediatrics, Translational Medicine Unit, Uniformed Services University, Bethesda, Maryland, USA
| | - Ryan Flanagan
- Department of Pediatrics, Translational Medicine Unit, Uniformed Services University, Bethesda, Maryland, USA
| | - Derek T Larson
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Naval Medical Center San Diego, San Diego, California, USA
- Alexander T. Augusta Military Medical Center, Fort Belvoir, Virginia, USA
| | - Evan C Ewers
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Alexander T. Augusta Military Medical Center, Fort Belvoir, Virginia, USA
| | | | - David Saunders
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Ryan C Maves
- Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
| | - Jeffrey Livezey
- Department of Pediatrics, Clinical Pharmacology and Medical Toxicology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | | | - Margaret Sanchez Edwards
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA
| | - Julia S Rozman
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA
| | - Robert J O’Connell
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Mark P Simons
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - David R Tribble
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Brian K Agan
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA
| | - Timothy H Burgess
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Simon D Pollett
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA
| |
Collapse
|
5
|
Scher AI, McGinley JS, VanDam LR, Campbell AM, Chai X, Collins B, Klimp SA, Finkel AG, Schwab K, Lipton RB, Johnson KW. Plasma calcitonin gene-related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion. Headache 2023; 63:1240-1250. [PMID: 37796114 DOI: 10.1111/head.14635] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 08/23/2023] [Accepted: 08/30/2023] [Indexed: 10/06/2023]
Abstract
OBJECTIVE The objective of this study was to characterize the utility of calcitonin gene-related peptide (CGRP) and nerve growth factor (NGF) as potential biomarkers for headache and pain disorders in the post-military deployment setting. BACKGROUND The need to improve recognition, assessment, and prognoses of individuals with posttraumatic headache or other pain has increased interest in the potential of CGRP and NGF as biomarkers. METHODS The Warrior Strong Study (NCT01847040) is an observational longitudinal study of United States-based soldiers who had recently returned from deployment to Afghanistan or Iraq from 2009 to 2014. The present nested cross-sectional analysis uses baseline data collected from soldiers returning to Fort Bragg, North Carolina. RESULTS In total, 264 soldiers (mean (standard deviation [SD] age 28.1 [6.4] years, 230/264 [87.1%] men, 171/263 [65.0%] White) were analyzed. Mean (SD) plasma levels of CGRP were 1.3 (1.1) pg/mL and mean levels of NGF were 1.4 (0.4) pg/mL. Age was negatively correlated with NGF (-0.01 pg/mL per year, p = 0.007) but was not associated with CGRP. Men had higher mean (SD) CGRP plasma levels than women (1.4 95% confidence interval [CI; 1.2] vs. 0.9 95% CI [0.5] pg/mL, p < 0.002, Kruskal-Wallis test). CGRP levels were lower in participants who had a headache at the time of the blood draw (1.0 [0.6] pg/mL vs. 1.4 [1.2] pg/mL, p = 0.024). NGF was lower in participants with continuous pain (all types; 1.2 [0.4] vs. 1.4 [0.4] pg/mL, p = 0.027) and was lower in participants with traumatic brain injury (TBI) + posttraumatic headache (PTH) versus TBI without PTH (1.3 [0.3] vs. 1.4 [0.4] pg/mL, p = 0.021). Otherwise, CGRP and NGF were not associated with migraine-like headache, TBI status, or headache burden as measured by the number of medical encounters in crude or adjusted models. CONCLUSION In this exploratory study, plasma levels of NGF and CGRP showed promise as biomarkers for headache and other types of pain. These findings need to be replicated in other cohorts.
Collapse
Affiliation(s)
- Ann I Scher
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | | | - Lyndsey R VanDam
- Pain Research, Eli Lilly and Company, Indianapolis, Indiana, USA
| | | | - Xiyun Chai
- Precision Medicine Neuroscience, AbbVie, Chicago, Illinois, USA
| | - Billy Collins
- US Public Health Service Commissioned Corps, Fayetteville, North Carolina, USA
| | - Scott A Klimp
- Womack Army Medical Center, Fort Bragg, North Carolina, USA
| | - Alan G Finkel
- Carolina Headache Institute, Durham, North Carolina, USA
| | - Karen Schwab
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | | | - Kirk W Johnson
- Pain Research, Eli Lilly and Company, Indianapolis, Indiana, USA
| |
Collapse
|
6
|
Fideli ÜS, Scher AI, Olsen C, Hisle-Gorman E. Assessing mean corpuscular volume as a screening tool for gestational vitamin B12 deficiency based on NHANES. INT J VITAM NUTR RES 2023. [PMID: 37469107 DOI: 10.1024/0300-9831/a000788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/21/2023]
Abstract
Vitamin B12 can lead to neurological deficits. We assessed whether the mean corpuscular volume (MCV) could be a sufficiently sensitive measurement for abnormal serum methylmalonic Acid (MMA) and total plasma homocysteine (tHCY) (biomarkers of vitamin B12 or folate deficiency) and if so, at what cutoff value. A total of 26,397 participants (12,730 males and 13,667 females) were included in the analysis. Weighted analysis was performed using NHANES data to calculate crude/adjusted associations between MCV-MMA/tHCY, using linear regression. Unadjusted odds ratios (OR) 95% CIs were estimated from logistic regression models. Receiver Operating Curve and the Youden Index were used to identify the MCV level that most accurately distinguished those with abnormal MMA and tHCY (dependent variables) from those without. A positive and significant correlation between MCV-MMA/tHCY was found in the general population between ages 18-85, 0.95 (95% C.I. 0.75-1.17) and 2.61 (95% C.I. 2.15-3.08). In pregnant women, for every unit increase in MCV there was a 19% increase in odds of abnormal MMA, OR 1.19 (95% C.I. 1.08-1.31), p=0.001 and the Area Under the Curve for MCV as a test for abnormal MMA was 78%. An MCV cutoff of 93.1 correctly identified abnormal MMA in pregnant women with 81% sensitivity and 77% specificity. In the general population the MCV test performed poorly in identifying abnormal MMA/tHCY. MCV is an inexpensive measurement that may be useful to screen asymptomatic pregnant women for vitamin B12 abnormalities. This may have a significant impact on reducing adverse neurological outcomes in their children.
Collapse
Affiliation(s)
- Ülgen S Fideli
- Department of Preventive Medicine and Biostatistics, F. Edward Hérbert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
| | - Ann I Scher
- Department of Preventive Medicine and Biostatistics, F. Edward Hérbert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
| | - Cara Olsen
- Department of Preventive Medicine and Biostatistics, F. Edward Hérbert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
| | - Elizabeth Hisle-Gorman
- Department of Preventive Medicine and Biostatistics, F. Edward Hérbert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
- Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
| |
Collapse
|
7
|
Richard SA, Pollett SD, Fries AC, Berjohn CM, Maves RC, Lalani T, Smith AG, Mody RM, Ganesan A, Colombo RE, Lindholm DA, Morris MJ, Huprikar N, Colombo CJ, Madar C, Jones M, Larson DT, Bazan SE, Mende K, Saunders D, Livezey J, Lanteri CA, Scher AI, Byrne C, Rusiecki J, Ewers E, Epsi NJ, Rozman JS, English C, Simons MP, Tribble DR, Agan BK, Burgess TH. Persistent COVID-19 Symptoms at 6 Months After Onset and the Role of Vaccination Before or After SARS-CoV-2 Infection. JAMA Netw Open 2023; 6:e2251360. [PMID: 36652247 PMCID: PMC9857077 DOI: 10.1001/jamanetworkopen.2022.51360] [Citation(s) in RCA: 24] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
IMPORTANCE Understanding the factors associated with post-COVID conditions is important for prevention. OBJECTIVE To identify characteristics associated with persistent post-COVID-19 symptoms and to describe post-COVID-19 medical encounters. DESIGN, SETTING, AND PARTICIPANTS This cohort study used data from the Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases With Pandemic Potential (EPICC) study implemented in the US military health system (MHS); MHS beneficiaries aged 18 years or older who tested positive for SARS-CoV-2 from February 28, 2020, through December 31, 2021, were analyzed, with 1-year follow-up. EXPOSURES SARS-CoV-2 infection. MAIN OUTCOMES AND MEASURES The outcomes analyzed included survey-reported symptoms through 6 months after SARS-CoV-2 infection and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnosis categories reported in medical records 6 months following SARS-CoV-2 infection vs 3 months before infection. RESULTS More than half of the 1832 participants in these analyses were aged 18 to 44 years (1226 [66.9%]; mean [SD] age, 40.5 [13.7] years), were male (1118 [61.0%]), were unvaccinated at the time of their infection (1413 [77.1%]), and had no comorbidities (1290 [70.4%]). A total of 728 participants (39.7%) had illness that lasted 28 days or longer (28-89 days: 364 [19.9%]; ≥90 days: 364 [19.9%]). Participants who were unvaccinated prior to infection (risk ratio [RR], 1.39; 95% CI, 1.04-1.85), reported moderate (RR, 1.80; 95% CI, 1.47-2.22) or severe (RR, 2.25; 95% CI, 1.80-2.81) initial illnesses, had more hospitalized days (RR per each day of hospitalization, 1.02; 95% CI, 1.00-1.03), and had a Charlson Comorbidity Index score of 5 or greater (RR, 1.55; 95% CI, 1.01-2.37) were more likely to report 28 or more days of symptoms. Among unvaccinated participants, postinfection vaccination was associated with a 41% lower risk of reporting symptoms at 6 months (RR, 0.59; 95% CI, 0.40-0.89). Participants had higher risk of pulmonary (RR, 2.00; 95% CI, 1.40-2.84), diabetes (RR, 1.46; 95% CI, 1.00-2.13), neurological (RR, 1.29; 95% CI, 1.02-1.64), and mental health-related medical encounters (RR, 1.28; 95% CI, 1.01-1.62) at 6 months after symptom onset than at baseline (before SARS-CoV-2 infection). CONCLUSIONS AND RELEVANCE In this cohort study, more severe acute illness, a higher Charlson Comorbidity Index score, and being unvaccinated were associated with a higher risk of reporting COVID-19 symptoms lasting 28 days or more. Participants with COVID-19 were more likely to seek medical care for diabetes, pulmonary, neurological, and mental health-related illness for at least 6 months after onset compared with their pre-COVID baseline health care use patterns. These findings may inform the risk-benefit ratio of COVID-19 vaccination policy.
Collapse
Affiliation(s)
- Stephanie A. Richard
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland
| | - Simon D. Pollett
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland
| | | | - Catherine M. Berjohn
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- Naval Medical Center San Diego, San Diego, California
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland
| | - Ryan C. Maves
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- Naval Medical Center San Diego, San Diego, California
| | - Tahaniyat Lalani
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland
- Naval Medical Center Portsmouth, Portsmouth, Virginia
| | | | - Rupal M. Mody
- William Beaumont Army Medical Center, Fort Bliss, Texas
| | - Anuradha Ganesan
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland
- Walter Reed National Military Medical Center, Bethesda, Maryland
| | - Rhonda E. Colombo
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- Madigan Army Medical Center, Joint Base Lewis-McChord, Washington
| | - David A. Lindholm
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- Brooke Army Medical Center, Joint Base San Antonio–Fort Sam Houston, Texas
| | - Michael J. Morris
- Brooke Army Medical Center, Joint Base San Antonio–Fort Sam Houston, Texas
| | - Nikhil Huprikar
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- Walter Reed National Military Medical Center, Bethesda, Maryland
| | - Christopher J. Colombo
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- Madigan Army Medical Center, Joint Base Lewis-McChord, Washington
| | | | - Milissa Jones
- Tripler Army Medical Center, Honolulu, Hawaii
- Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
| | - Derek T. Larson
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- Fort Belvoir Community Hospital, Fort Belvoir, Virginia
| | | | - Katrin Mende
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland
- Brooke Army Medical Center, Joint Base San Antonio–Fort Sam Houston, Texas
| | - David Saunders
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland
| | - Jeffrey Livezey
- Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
| | - Charlotte A. Lanteri
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
| | | | | | | | - Evan Ewers
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- Fort Belvoir Community Hospital, Fort Belvoir, Virginia
| | - Nusrat J. Epsi
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland
| | - Julia S. Rozman
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland
| | - Caroline English
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland
| | - Mark P. Simons
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
| | - David R. Tribble
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
| | - Brian K. Agan
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland
| | - Timothy H. Burgess
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
| |
Collapse
|
8
|
Bytnar JA, Lin J, Theeler BJ, Scher AI, Shriver CD, Zhu K. The relationship between prior psychiatric diagnosis and brain cancer diagnosis in the U.S. military health system. Cancer Causes Control 2022; 33:1135-1144. [PMID: 35838810 DOI: 10.1007/s10552-022-01608-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Accepted: 06/29/2022] [Indexed: 11/27/2022]
Abstract
PURPOSE Prior research suggested the increased likelihood of brain cancer diagnosis following certain psychiatric diagnoses. This association may result from detection bias or suggest an early sign for brain cancer. This study investigated whether psychiatric illness may be an early manifestation of brain cancer while considering potential effects of detection bias. METHODS This case-control study used the data from the Department of Defense's Central Cancer Registry and the Military Health System Data Repository. Four cancer-free controls and one negative-outcome control (cancers not associated with psychiatric illness) were matched to each brain cancer case diagnosed from 1998 to 2013 by age, sex, race, and military status. The groups were compared in the likelihood of having a pre-existing psychiatric diagnosis using conditional logistic regression. RESULTS We found a significant association of psychiatric illnesses with brain cancer (Odds Ratio (OR) = 2.63, 95% confidence interval (CI) = 2.18-3.16) and other cancers (OR = 1.80, 95% CI = 1.49-2.19), compared to non-cancer controls. The association was stronger for psychiatric diagnoses within three months before cancer (brain cancer: OR = 26.77, 95% CI = 15.40-46.53; other cancers: OR = 4.12, 95% CI = 1.96-8.65). The association with psychiatric disorders within 3 months were higher for small brain tumors (OR = 128.32, 95% CI = 17.28-952.92 compared to non-cancer controls) while the OR was 2.79 for other cancers (95% CI = 0.86-8.99 compared to non-cancer controls). CONCLUSION Our findings suggest an association between diagnosed psychiatric illnesses and subsequent brain cancer diagnosis, which may not be solely explained by detection bias. Psychiatric illness might be a sign for early detection of brain cancer beyond the potential effects of detection bias.
Collapse
Affiliation(s)
- Julie A Bytnar
- Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.,The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA
| | - Jie Lin
- Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.,The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA.,Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Brett J Theeler
- Department of Neurology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Ann I Scher
- Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Craig D Shriver
- Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Kangmin Zhu
- Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. .,The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA. .,Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
| |
Collapse
|
9
|
Scher AI, Berjohn CM, Byrne C, Colombo RE, Colombo CJ, Sanchez Edwards M, Ewers EC, Ganesan A, Jones M, Larson DT, Libraty D, Lindholm DA, Madar CS, Maldonado CJ, Maves RC, Mende K, Richard SA, Rozman JS, Rusiecki J, Smith A, Simons M, Tribble D, Agan B, Burgess TH, Pollett SD. An Analysis of SARS-CoV-2 Vaccine Reactogenicity: Variation by Type, Dose, and History, Severity, and Recency of Prior SARS-CoV-2 Infection. Open Forum Infect Dis 2022; 9:ofac314. [PMID: 35899278 PMCID: PMC9278193 DOI: 10.1093/ofid/ofac314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Accepted: 06/24/2022] [Indexed: 11/28/2022] Open
Abstract
Background There is limited information on the functional consequences of coronavirus disease 2019 (COVID-19) vaccine side effects. To support patient counseling and public health messaging, we describe the risk and correlates of COVID-19 vaccine side effects sufficient to prevent work or usual activities and/or lead to medical care (“severe” side effects). Methods The EPICC study is a longitudinal cohort study of Military Healthcare System beneficiaries including active duty service members, dependents, and retirees. We studied 2789 adults who were vaccinated between December 2020 and December 2021. Results Severe side effects were most common with the Ad26.COV2.S (Janssen/Johnson and Johnson) vaccine, followed by mRNA-1273 (Moderna) then BNT162b2 (Pfizer/BioNTech). Severe side effects were more common after the second than first dose (11% vs 4%; P < .001). First (but not second) dose side effects were more common in those with vs without prior severe acute respiratory syndrome coronavirus 2 infection (9% vs 2%; adjusted odds ratio [aOR], 5.84; 95% CI, 3.8–9.1), particularly if the prior illness was severe or critical (13% vs 2%; aOR, 10.57; 95% CI, 5.5–20.1) or resulted in inpatient care (17% vs 2%; aOR, 19.3; 95% CI, 5.1–72.5). Side effects were more common in women than men but not otherwise related to demographic factors. Conclusions Vaccine side effects sufficient to prevent usual activities were more common after the second than first dose and varied by vaccine type. First dose side effects were more likely in those with a history of COVID-19—particularly if that prior illness was severe or associated with inpatient care. These findings may assist clinicians and patients by providing a real-world evaluation of the likelihood of experiencing impactful postvaccine symptoms.
Collapse
Affiliation(s)
- Ann I Scher
- Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
| | - Catherine M Berjohn
- Naval Medical Center San Diego , San Diego, CA , USA
- Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
| | - Celia Byrne
- Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
| | - Rhonda E Colombo
- Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc ., Bethesda, MD , USA
- Madigan Army Medical Center , Joint Base Lewis McChord, WA , USA
| | - Christopher J Colombo
- Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
- Madigan Army Medical Center , Joint Base Lewis McChord, WA , USA
| | - Margaret Sanchez Edwards
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc ., Bethesda, MD , USA
| | - Evan C Ewers
- Fort Belvoir Community Hospital , Fort Belvoir, VA , USA
| | - Anuradha Ganesan
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc ., Bethesda, MD , USA
- Walter Reed National Military Medical Center , Bethesda, MD , USA
| | | | - Derek T Larson
- Naval Medical Center San Diego , San Diego, CA , USA
- Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
- Fort Belvoir Community Hospital , Fort Belvoir, VA , USA
| | - Daniel Libraty
- Naval Medical Center San Diego , San Diego, CA , USA
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc ., Bethesda, MD , USA
| | - David A Lindholm
- Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
- Brooke Army Medical Center , JBSA Ft Sam Houston, TX , USA
| | - Cristian S Madar
- Walter Reed National Military Medical Center , Bethesda, MD , USA
| | | | - Ryan C Maves
- Naval Medical Center San Diego , San Diego, CA , USA
- Department of Medicine, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
| | - Katrin Mende
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc ., Bethesda, MD , USA
- Brooke Army Medical Center , JBSA Ft Sam Houston, TX , USA
| | - Stephanie A Richard
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc ., Bethesda, MD , USA
| | - Julia S Rozman
- Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc ., Bethesda, MD , USA
| | - Jennifer Rusiecki
- Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
| | - Alfred Smith
- Naval Medical Center Portsmouth , Portsmouth, VA , USA
| | - Mark Simons
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
| | - David Tribble
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
| | - Brian Agan
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc ., Bethesda, MD , USA
| | - Timothy H Burgess
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
| | - Simon D Pollett
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, MD , USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc ., Bethesda, MD , USA
| | | |
Collapse
|
10
|
Epsi NJ, Richard SA, Lindholm DA, Mende K, Ganesan A, Huprikar N, Lalani T, Fries AC, Maves RC, Colombo RE, Larson DT, Smith A, Chi SW, Maldonado CJ, Ewers EC, Jones MU, Berjohn CM, Libraty DH, Edwards MS, English C, Rozman JS, Mody RM, Colombo CJ, Samuels EC, Nwachukwu P, Tso MS, Scher AI, Byrne C, Rusiecki J, Simons MP, Tribble D, Broder CC, Agan BK, Burgess TH, Laing ED, Pollett SD. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. Clin Infect Dis 2022; 76:e439-e449. [PMID: 35608504 PMCID: PMC9213853 DOI: 10.1093/cid/ciac392] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 04/29/2022] [Accepted: 05/17/2022] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Comparison of humoral responses in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinees, those with SARS-CoV-2 infection, or combinations of vaccine/ infection ("hybrid immunity") may clarify predictors of vaccine immunogenicity. METHODS We studied 2660 US Military Health System beneficiaries with a history of SARS-CoV-2 infection-alone (n = 705), vaccination-alone (n = 932), vaccine-after-infection (n = 869), and vaccine-breakthrough-infection (n = 154). Peak anti-spike-immunoglobulin G (IgG) responses through 183 days were compared, with adjustment for vaccine product, demography, and comorbidities. We excluded those with evidence of clinical or subclinical SARS-CoV-2 reinfection from all groups. RESULTS Multivariable regression results indicated that vaccine-after-infection anti-spike-IgG responses were higher than infection-alone (P < .01), regardless of prior infection severity. An increased time between infection and vaccination was associated with greater post-vaccination IgG response (P < .01). Vaccination-alone elicited a greater IgG response but more rapid waning of IgG (P < .01) compared with infection-alone (P < .01). BNT162b2 and mRNA-1273 vaccine-receipt was associated with greater IgG responses compared with JNJ-78436735 vaccine-receipt (P < .01), regardless of infection history. Those with vaccine-after-infection or vaccine-breakthrough-infection had a more durable anti-spike-IgG response compared to infection-alone (P < .01). CONCLUSIONS Vaccine-receipt elicited higher anti-spike-IgG responses than infection-alone, although IgG levels waned faster in those vaccinated (compared to infection-alone). Vaccine-after-infection elicits a greater humoral response compared with vaccine or infection alone; and the timing, but not disease severity, of prior infection predicted these post-vaccination IgG responses. While differences between groups were small in magnitude, these results offer insights into vaccine immunogenicity variations that may help inform vaccination timing strategies.
Collapse
Affiliation(s)
- Nusrat J Epsi
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA,Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA
| | - Stephanie A Richard
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA,Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA
| | - David A Lindholm
- Brooke Army Medical Center, Fort Sam Houston, Texas, USA,Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Katrin Mende
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA,Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA,Brooke Army Medical Center, Fort Sam Houston, Texas, USA
| | - Anuradha Ganesan
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA,Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA,Walter Reed National Military Medical Center, Bethesda, Maryland, USA
| | - Nikhil Huprikar
- Walter Reed National Military Medical Center, Bethesda, Maryland, USA
| | - Tahaniyat Lalani
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA,Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA,Naval Medical Center Portsmouth, Portsmouth, Virginia, USA
| | - Anthony C Fries
- US Air Force School of Aerospace Medicine, Dayton, Ohio, USA
| | - Ryan C Maves
- Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Rhonda E Colombo
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA,Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA,Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA,Madigan Army Medical Center, Joint Base Lewis McChord, Washington, USA
| | - Derek T Larson
- Fort Belvoir Community Hospital, Fort Belvoir, Virginia, USA,Naval Medical Center San Diego, San Diego, California, USA
| | - Alfred Smith
- Naval Medical Center Portsmouth, Portsmouth, Virginia, USA
| | - Sharon W Chi
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA,Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA,Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | | | - Evan C Ewers
- Fort Belvoir Community Hospital, Fort Belvoir, Virginia, USA
| | | | - Catherine M Berjohn
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA,Naval Medical Center San Diego, San Diego, California, USA
| | - Daniel H Libraty
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA,Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA,Naval Medical Center San Diego, San Diego, California, USA
| | - Margaret Sanchez Edwards
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA,Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA
| | - Caroline English
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA,Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA
| | - Julia S Rozman
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA,Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA
| | - Rupal M Mody
- William Beaumont Army Medical Center, El Paso, Texas, USA
| | - Christopher J Colombo
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA,Madigan Army Medical Center, Joint Base Lewis McChord, Washington, USA
| | - Emily C Samuels
- Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Princess Nwachukwu
- Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Marana S Tso
- Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Ann I Scher
- Department of Preventive Medicine & Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Celia Byrne
- Department of Preventive Medicine & Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Jennifer Rusiecki
- Department of Preventive Medicine & Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Mark P Simons
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - David Tribble
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Christopher C Broder
- Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Brian K Agan
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA,Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA
| | - Timothy H Burgess
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Eric D Laing
- Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Simon D Pollett
- Correspondence: Simon Pollett, MBBS, 6720A Rockledge Drive, Suite 250, Bethesda, MD 20817, USA ()
| | | |
Collapse
|
11
|
Scher AI, Bendtsen L. Patient-Centered Treatment of Chronic Migraine With Medication Overuse: More Is Not Always Better. Neurology 2022; 98:563-564. [PMID: 35169016 DOI: 10.1212/wnl.0000000000200252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Ann I Scher
- From the Department of Preventive Medicine and Biostatistics (A.I.S.), Uniformed Services University, Bethesda MD; Department of Neurology (L.B.), Danish Headache Centre, Glostrup Hospital, University of Copenhagen, Denmark.
| | - Lars Bendtsen
- From the Department of Preventive Medicine and Biostatistics (A.I.S.), Uniformed Services University, Bethesda MD; Department of Neurology (L.B.), Danish Headache Centre, Glostrup Hospital, University of Copenhagen, Denmark
| |
Collapse
|
12
|
Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, Elledge SJ, Niebuhr DW, Scher AI, Munger KL, Ascherio A. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 2022; 375:296-301. [PMID: 35025605 DOI: 10.1126/science.abj8222] [Citation(s) in RCA: 759] [Impact Index Per Article: 379.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system of unknown etiology. We tested the hypothesis that MS is caused by Epstein-Barr virus (EBV) in a cohort comprising more than 10 million young adults on active duty in the US military, 955 of whom were diagnosed with MS during their period of service. Risk of MS increased 32-fold after infection with EBV but was not increased after infection with other viruses, including the similarly transmitted cytomegalovirus. Serum levels of neurofilament light chain, a biomarker of neuroaxonal degeneration, increased only after EBV seroconversion. These findings cannot be explained by any known risk factor for MS and suggest EBV as the leading cause of MS.
Collapse
Affiliation(s)
- Kjetil Bjornevik
- Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - Marianna Cortese
- Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - Brian C Healy
- Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.,Department of Neurology, Harvard Medical School, Boston, MA, USA.,Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA
| | - Jens Kuhle
- Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland
| | - Michael J Mina
- Division of Genetics, Brigham and Women's Hospital, Howard Hughes Medical Institute, Department of Genetics, and Program in Virology, Harvard Medical School, Boston, MA, USA.,Center for Communicable Disease Dynamics, Department of Epidemiology, and Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.,Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Yumei Leng
- Division of Genetics, Brigham and Women's Hospital, Howard Hughes Medical Institute, Department of Genetics, and Program in Virology, Harvard Medical School, Boston, MA, USA
| | - Stephen J Elledge
- Division of Genetics, Brigham and Women's Hospital, Howard Hughes Medical Institute, Department of Genetics, and Program in Virology, Harvard Medical School, Boston, MA, USA
| | - David W Niebuhr
- Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Ann I Scher
- Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Kassandra L Munger
- Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - Alberto Ascherio
- Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, USA.,Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.,Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA
| |
Collapse
|
13
|
Ashina H, Eigenbrodt AK, Seifert T, Sinclair AJ, Scher AI, Schytz HW, Lee MJ, De Icco R, Finkel AG, Ashina M. Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment. Lancet Neurol 2021; 20:460-469. [PMID: 34022171 DOI: 10.1016/s1474-4422(21)00094-6] [Citation(s) in RCA: 42] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 03/08/2021] [Accepted: 03/09/2021] [Indexed: 12/19/2022]
Abstract
Post-traumatic headache is a common sequela of traumatic brain injury and is classified as a secondary headache disorder. In the past 10 years, considerable progress has been made to better understand the clinical features of this disorder, generating momentum to identify effective therapies. Post-traumatic headache is increasingly being recognised as a heterogeneous headache disorder, with patients often classified into subphenotypes that might be more responsive to specific therapies. Such considerations are not accounted for in three iterations of diagnostic criteria published by the International Headache Society. The scarcity of evidence-based approaches has left clinicians to choose therapies on the basis of the primary headache phenotype (eg, migraine and tension-type headache) and that are most compatible with the clinical picture. A concerted effort is needed to address these shortcomings and should include large prospective cohort studies as well as randomised controlled trials. This approach, in turn, will result in better disease characterisation and availability of evidence-based treatment options.
Collapse
Affiliation(s)
- Håkan Ashina
- Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Anna K Eigenbrodt
- Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | | | - Alexandra J Sinclair
- Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
| | - Ann I Scher
- Department of Preventive Medicine and Biostatistics, Uniformed Services University, Bethesda, MD, USA
| | - Henrik W Schytz
- Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Mi Ji Lee
- Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Roberto De Icco
- Headache Science and Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
| | | | - Messoud Ashina
- Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Danish Knowledge Center on Headache Disorders, Glostrup, Denmark; Department of Nervous Diseases of the Institute of Professional Education, IM Sechenov First Moscow State Medical University, Moscow, Russia; Department of Neurology, Azerbaijan Medical University, Baku, Azerbaijan.
| |
Collapse
|
14
|
Scher AI, McGinley JS, Wirth RJ, Lipton RB, Terrio H, Brenner LA, Cole WR, Schwab K. Headache complexity (number of symptom features) differentiates post-traumatic from non-traumatic headaches. Cephalalgia 2020; 41:582-592. [PMID: 33242991 DOI: 10.1177/0333102420974352] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
BACKGROUND Post-traumatic headaches are a common sequela of mild traumatic brain injury (concussion). It is unclear whether or how these headaches differ phenotypically from primary headaches. OBJECTIVE Determine whether there is an overarching unobserved latent trait that drives the expression of observed features of post-traumatic headache and other headaches. METHODS Data from this post-hoc analysis come from the Warrior Strong Cohort Study conducted from 2010 through 2015. Approximately 25,000 soldiers were screened for concussion history at routine post-deployment health assessments. A random sample was invited to participate, enrolling 1567. Twelve observed headache phenotypic features were used to measure "headache complexity", the latent trait of clinical interest, using single factor confirmatory factor analysis. We compared headache complexity between groups and determined whether headache complexity predicted accessing medical care for headache. RESULTS Of 1094 soldiers with headaches, 198 were classified as having post-traumatic headache. These headaches were compared to those in the other soldiers (647 without concussion history and 249 with concussion history). Soldiers with post-traumatic headache had greater endorsement of all 12 headache features compared to the soldiers with non-concussive headaches. The confirmatory factor analysis showed good model fit (χ2 (51) = 95.59, p = 0.0002, RMSEA = 0.03, comparative fit index = 0.99, and Tucker-Lewis index = 0.99), providing empirical support for the headache complexity construct. Soldier groups differed in their mean headache complexity level (p < 0.001) such that post-traumatic headache soldiers had greater headache complexity compared to non-concussed soldiers (standardized mean difference = 0.91, 95% confidence interval: 0.72-1.09, p < 0.001 and to concussed soldiers with coincidental headaches standardized mean difference = 0.75, 95% confidence interval: 0.53-0.96, p < 0.001). Increasing headache complexity predicted medical encounters for headache (odds ratio = 1.87, 95% confidence interval: 1.49-2.35, p < 0.001) and migraine (odds ratio = 3.74, 95% confidence interval: 2.33-5.98, p < 0.001) during the year following deployment.Conclusions and relevance: The current study provided support for a single latent trait, characterized by observed headache symptoms, that differentiates between concussive and non-concussive headaches and predicts use of medical care for headache. The single trait confirmatory factor analysis suggests that post-traumatic headaches differ from non-concussive headaches by severity more than kind, based on the symptoms assessed.ClinicalTrials.gov identifier NCT01847040.
Collapse
Affiliation(s)
- Ann I Scher
- 1685Uniformed Services University, Bethesda, MD, USA
| | | | - R J Wirth
- Vector Psychometric Group, LLC, Chapel Hill, NC, USA
| | | | - Heidi Terrio
- 19909Evans Army Community Hospital, Colorado Springs, CO, USA.,VA (Veterans Affairs) Puget Sound Health System, Seattle, WA, USA
| | - Lisa A Brenner
- Departments of Physical Medicine and Rehabilitation, Psychiatry, and Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.,VA (Veterans Affairs) Rocky Mountain Mental Illness Research Education and Clinical Center, Aurora, CO, USA
| | - Wesley R Cole
- Intrepid Spirit Center, 19921Womack Army Medical Center, Fort Bragg, NC, USA
| | - Karen Schwab
- 1685Uniformed Services University, Bethesda, MD, USA
| |
Collapse
|
15
|
Bjornevik K, Munger KL, Cortese M, Barro C, Healy BC, Niebuhr DW, Scher AI, Kuhle J, Ascherio A. Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. JAMA Neurol 2020; 77:58-64. [PMID: 31515562 DOI: 10.1001/jamaneurol.2019.3238] [Citation(s) in RCA: 122] [Impact Index Per Article: 30.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Importance Unrecognized demyelinating events often precede the clinical onset of multiple sclerosis (MS). Identification of these events at the time of occurrence would have implications for early diagnosis and the search of causal factors for the disease. Objective To assess whether serum neurofilament light chain (sNfL) levels are elevated before the clinical MS onset. Design, Setting, and Participants Nested case-control study among US military personnel who have serum samples stored in the US Department of Defense Serum Repository. Serum samples were collected from 2000 to 2011; sNfL assays and data analyses were performed from 2018 to 2019. We selected 60 case patients with MS who either had 2 samples collected before onset (mean follow-up, 6.3 years) or 1 sample collected before and 1 after onset (mean follow-up, 1.3 years), among 245 previously identified case patients. For each case, we randomly selected 1 of 2 previously identified control individuals matched by age, sex, race/ethnicity, and dates of sample collection. The sample size was chosen based on the available funding. Exposures Serum NfL concentrations measured using an ultrasensitive single-molecule array assay (Simoa). Main Outcomes and Measurements Log-transformed sNfL concentrations in case patients and control individuals compared using conditional logistic regression and linear mixed models. Results Mean age at baseline was 27.5 years, and 92 of 120 participants (76.7%) were men. Serum NfL levels were higher in case patients with MS compared with their matched control individuals in samples drawn a median of 6 years (range, 4-10 years) before the clinical onset (median, 16.7 pg/mL; interquartile range [IQR], 12.6-23.1 pg/mL vs 15.2 pg/m; IQR, 10.3-19.9 pg/mL; P = .04). This difference increased with decreasing time to the case clinical onset (estimated coefficient for interaction with time = 0.063; P = .008). A within-person increase in presymptomatic sNfL levels was associated with higher MS risk (rate ratio for ≥5 pg/mL increase, 7.50; 95% CI, 1.72-32.80). The clinical onset was associated with a marked increase in sNfL levels (median, 25.0; IQR, 17.1-41.3 vs 45.1; IQR, 27.0-102.7 pg/mL for presymptomatic and postonset MS samples; P = .009). Conclusions and Relevance The levels of sNfL were increased 6 years before the clinical MS onset, indicating that MS may have a prodromal phase lasting several years and that neuroaxonal damage occurs already during this phase.
Collapse
Affiliation(s)
- Kjetil Bjornevik
- Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
| | - Kassandra L Munger
- Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
| | - Marianna Cortese
- Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
| | - Christian Barro
- Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Brian C Healy
- Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, Massachusetts.,Department of Neurology, Harvard Medical School, Boston, Massachusetts.,Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts
| | - David W Niebuhr
- Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
| | - Ann I Scher
- Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland
| | - Jens Kuhle
- Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Alberto Ascherio
- Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.,Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.,Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
16
|
Remigio-Baker RA, Kiser S, Ferdosi H, Gregory E, Engel S, Sebesta S, Beauchamp D, Malik S, Scher AI, Hinds SR. Current patterns of primary care provider practices for the treatment of post-traumatic headache in active duty military settings. PLoS One 2020; 15:e0236762. [PMID: 32706834 PMCID: PMC7380628 DOI: 10.1371/journal.pone.0236762] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Accepted: 07/11/2020] [Indexed: 11/18/2022] Open
Abstract
Objective To provide a preliminary assessment of the current clinical practice for the treatment of post-traumatic headache following concussion in military primary health care settings. Background Headache is one of the most common symptoms post-concussion; however, little is known of the current clinical practices of primary care providers (on the treatment of post-traumatic headache), particularly in military settings. Methods Study participants were primary care providers (n = 65) who treated active duty Service members suffering from post-traumatic headache at two military installations. Qualitative data gathered via semi-structured interviews were used to describe provider practices and experience in treating patients with post-traumatic headache. Results Some patterns of care across primary care providers treating post-traumatic headache were consistent with the Department of Defense-recommended clinical recommendation (e.g., recommendation of both pharmacological and non-pharmacological treatment [89.4%]; engaging in follow-up care [100%]). Differences existed in timing of follow-up from initial visit [16.9% reporting within 24 hours; 21.5% reporting within 48–72 hours; and 26.2% reporting more than 1 week], the factors contributing to the type of care given (e.g., symptomatology [33.0%], injury characteristic [24.2%], patient characteristic [13.2%]) and the need for referral to higher level of care (e.g., symptomatology [44.6%], treatment failure [25.0%]). These variations may be indicative of individualized treatment which would be compliant with best clinical practice. Conclusion The results of this study demonstrate the current clinical practice in military primary care settings for the treatment of post-traumatic headache which can potentially inform and improve implementation of provider training and education.
Collapse
Affiliation(s)
- Rosemay A. Remigio-Baker
- Defense and Veterans Brain Injury Center, Silver Spring, MD, United States of America
- Henry Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States of America
- Naval Hospital Camp Pendleton, Camp Pendleton, CA, United States of America
- * E-mail:
| | - Seth Kiser
- Defense and Veterans Brain Injury Center, Silver Spring, MD, United States of America
- General Dynamics Information Technology, Falls Church, VA, United States of America
| | - Hamid Ferdosi
- Defense and Veterans Brain Injury Center, Silver Spring, MD, United States of America
- General Dynamics Information Technology, Falls Church, VA, United States of America
| | - Emma Gregory
- Defense and Veterans Brain Injury Center, Silver Spring, MD, United States of America
| | - Scot Engel
- Fort Hood, Intrepid Spirit Center, Ft Hood, TX, United States of America
| | - Sean Sebesta
- Fort Bliss, Intrepid Spirit Center, Ft Bliss, TX, United States of America
| | - Daniel Beauchamp
- Fort Bliss, Intrepid Spirit Center, Ft Bliss, TX, United States of America
| | - Saafan Malik
- Defense and Veterans Brain Injury Center, Silver Spring, MD, United States of America
| | - Ann I. Scher
- Preventive Medicine & Biostatistics, Uniformed Services University, Bethesda, MD, United States of America
| | - Sidney R. Hinds
- Neurology, Uniformed Services University, Bethesda, MD, United States of America
| |
Collapse
|
17
|
Abstract
OBJECTIVE To determine the prevalence of hypnic headache. BACKGROUND The exact prevalence of hypnic headache is unknown since there are no published population-based prevalence studies. METHODS This study was a pilot for the SAGA cohort study, a population-based study on life stressors and various indices of health. Of 1398 invited adults, 921 (66%) participated; 402 men (average age 45.6 years, SD 13.2) and 519 women (52.6 years, SD 11.1). Subjects answered a headache questionnaire including a screening question for hypnic headache. "Do you have a headache that occurs only during sleep and causes wakening?". Diagnosis of hypnic headache was made by clinical interview using ICHD-3 criteria. RESULTS Among 921 participants, six screened positive for hypnic headache, of those two 0.22% (95% CI 0.06-0.79%) had probable hypnic headache and none had definite hypnic headache. CONCLUSION Confirming that hypnic headache is rare, these data suggest a 0.22% prevalence of probable hypnic headache.
Collapse
Affiliation(s)
- Jon H Eliasson
- Department of Neurology, Centralsjukhuset Kristianstad, Kristianstad, Sweden
| | - Ann I Scher
- Department of Neurology, Albert Einstein College of Medicine of Yeshiva University, Bronx, USA
| | - Dawn C Buse
- Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, USA
| | | | - Richard B Lipton
- Department of Neurology, Albert Einstein College of Medicine of Yeshiva University, Bronx, USA
| | - Lenore J Launer
- Laboratory of Epidemiology and Population Science, National Institute on Aging, National Institute of Health, Bethesda, USA
| | | | - Larus S Gudmundsson
- Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland
| |
Collapse
|
18
|
Daniels CA, Olsen CH, Scher AI, McKay PL, Niebuhr DW. Severe Upper Limb Injuries in U.S. Military Personnel: Incidence, Risk Factor and Outcomes. Mil Med 2020; 185:e146-e153. [PMID: 31197319 DOI: 10.1093/milmed/usz139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Revised: 05/10/2019] [Accepted: 05/30/2019] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Severe upper limb injuries (SULI) may pose a significant public health challenge for the military; however, SULI has not been previously defined or studied in the US military. Objective: Determine SULI incidence, risk factors, and outcomes. MATERIALS AND METHODS Active Component (AC) U.S. military personnel who served during January 1, 2003 to December 31, 2012 who met the case definition for SULI (N = 213,745) and a random sample from the same population without SULI were included. Data from the Defense Medical Surveillance System and Defense Medical Epidemiology Database was used to calculate incidence. Multiple logistic regression and Cox proportional hazards models were used to analyze SULI risk factors and attrition. RESULTS SULI incidence was 15/1,000 person-years. Higher SULI risk was observed in men (OR 1.25; 95% CI 1.22-1.27), age 25-29 (OR 1.07; 95% CI 1.05-1.09) compared to age 20-24, E5-E9 (OR 1.14; 95% CI 1.12-1.17) compared to E1-E4, serving in Coast guard (OR 1.62; 95% CI 1.56-1.68) and Air Force (OR 1.17; 95% CI 1.14-1.19) relative to Army and with a deployment history (OR 2.16, 95% CI 2.12-2.19) while SULI risk was lower for blacks (OR 0.91; 95% CI 0.90-0.93) and those in the "other race" category (HR 0.81; 95% CI 0.80-0.84) compared to whites. SULI was associated with 23% increased risk of attrition (HR 1.23; 95% CI 1.22-1.24). CONCLUSION The study findings provide preliminary evidence on the incidence, natural history and distribution of SULI in this population. The findings indicate SULI may impact readiness and result in premature military separation.
Collapse
Affiliation(s)
- Colleen A Daniels
- Department of Preventive Medicine and Biostatistics, F.E. Hebert School of Medicine, Uniformed Services University, 4301 Jones Bridge Road, Bethesda, MD 20814.,Medical Education and Training Campus, Bldg. 1364, Rm. 4-424B, 3488 Garden Avenue, Fort Sam Houston, TX 78234
| | - Cara H Olsen
- Department of Preventive Medicine and Biostatistics, F.E. Hebert School of Medicine, Uniformed Services University, 4301 Jones Bridge Road, Bethesda, MD 20814
| | - Ann I Scher
- Department of Preventive Medicine and Biostatistics, F.E. Hebert School of Medicine, Uniformed Services University, 4301 Jones Bridge Road, Bethesda, MD 20814
| | - Patricia L McKay
- Department of Surgery, F.E. Hebert School of Medicine, Uniformed Services University, 4301 Jones Bridge Road, Bethesda, MD 20814
| | - David W Niebuhr
- Department of Preventive Medicine and Biostatistics, F.E. Hebert School of Medicine, Uniformed Services University, 4301 Jones Bridge Road, Bethesda, MD 20814
| |
Collapse
|
19
|
Metti A, Schwab K, Finkel A, Pazdan R, Brenner L, Cole W, Terrio H, Scher AI. Posttraumatic vs nontraumatic headaches: A phenotypic analysis in a military population. Neurology 2020; 94:e1137-e1146. [PMID: 31924681 DOI: 10.1212/wnl.0000000000008935] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Accepted: 09/12/2019] [Indexed: 01/03/2023] Open
Abstract
OBJECTIVE To describe and compare phenotypic features of posttraumatic headaches (PTH) and headaches unrelated to concussion. METHODS Participants are a random sample of recently deployed soldiers from the Warrior Strong cohort, consisting of soldiers with (n = 557) and without (n = 1,030) a history of a recent mild traumatic brain injury (mTBI; concussion). mTBI+ soldiers were subdivided as PTH+ (n = 230) and PTH- (n = 327). Headache classification was based on a detailed phenotypic questionnaire. Medical encounters for headache were documented for the year after deployment. RESULTS The findings here are limited to the soldiers with headaches, consisting of 94% of the mTBI+ soldiers and 76% of the mTBI- soldiers. Other than headache duration, all headache/migraine features were more common or more severe in the PTH+ group compared to the nonconcussed group (mTBI-) and compared to the concussed group with nontraumatic headaches (PTH-). Headaches were largely similar in the mTBI- and PTH- groups. The features most specific to PTH+ included allodynia, visual aura, sensory aura, daily headache, and continuous headache. Medical consultation for headache was most common in the PTH+ group (62%) vs the PTH- group (20%) or the mTBI- group (13%) (p < 0.008). CONCLUSIONS In this cohort of recently deployed soldiers, PTHs are more severe, frequent, and migraine-like and more often associated with medical consultation compared to headaches presumed unrelated to concussion. Future observational studies are needed to verify and characterize the PTH phenotype, which could be followed by treatment trials with appropriate and possibly novel outcomes for prespecified subgroups. CLINICALTRIALSGOV IDENTIFIER NCT01847040.
Collapse
Affiliation(s)
- Andrea Metti
- From the Metti Consulting Company (A.M.), Pittsburgh, PA; Defense and Veterans Brain Injury Center (K.S., A.F., R.P.), Silver Spring, MD; 9Line, LLC (K.S.), Tampa, FL; Carolina Headache Institute (A.F.), Durham, NC; Departments of Physical Medicine and Rehabilitation, Psychiatry, and Neurology (L.B.), Anschutz Medical Campus, University of Colorado Aurora; Marcus Institute for Brain Health (L.B.), Aurora; VHA Rocky Mountain Mental Illness Research Education and Clinical Center (L.B.), Denver, CO; Womack Army Medical Center (A.F., W.C.), Fort Bragg, NC; Evans Army Community Hospital (H.T.), Colorado Springs, CO; and Uniformed Services University of the Health Sciences (A.I.S.), Bethesda MD
| | - Karen Schwab
- From the Metti Consulting Company (A.M.), Pittsburgh, PA; Defense and Veterans Brain Injury Center (K.S., A.F., R.P.), Silver Spring, MD; 9Line, LLC (K.S.), Tampa, FL; Carolina Headache Institute (A.F.), Durham, NC; Departments of Physical Medicine and Rehabilitation, Psychiatry, and Neurology (L.B.), Anschutz Medical Campus, University of Colorado Aurora; Marcus Institute for Brain Health (L.B.), Aurora; VHA Rocky Mountain Mental Illness Research Education and Clinical Center (L.B.), Denver, CO; Womack Army Medical Center (A.F., W.C.), Fort Bragg, NC; Evans Army Community Hospital (H.T.), Colorado Springs, CO; and Uniformed Services University of the Health Sciences (A.I.S.), Bethesda MD
| | - Alan Finkel
- From the Metti Consulting Company (A.M.), Pittsburgh, PA; Defense and Veterans Brain Injury Center (K.S., A.F., R.P.), Silver Spring, MD; 9Line, LLC (K.S.), Tampa, FL; Carolina Headache Institute (A.F.), Durham, NC; Departments of Physical Medicine and Rehabilitation, Psychiatry, and Neurology (L.B.), Anschutz Medical Campus, University of Colorado Aurora; Marcus Institute for Brain Health (L.B.), Aurora; VHA Rocky Mountain Mental Illness Research Education and Clinical Center (L.B.), Denver, CO; Womack Army Medical Center (A.F., W.C.), Fort Bragg, NC; Evans Army Community Hospital (H.T.), Colorado Springs, CO; and Uniformed Services University of the Health Sciences (A.I.S.), Bethesda MD
| | - Renee Pazdan
- From the Metti Consulting Company (A.M.), Pittsburgh, PA; Defense and Veterans Brain Injury Center (K.S., A.F., R.P.), Silver Spring, MD; 9Line, LLC (K.S.), Tampa, FL; Carolina Headache Institute (A.F.), Durham, NC; Departments of Physical Medicine and Rehabilitation, Psychiatry, and Neurology (L.B.), Anschutz Medical Campus, University of Colorado Aurora; Marcus Institute for Brain Health (L.B.), Aurora; VHA Rocky Mountain Mental Illness Research Education and Clinical Center (L.B.), Denver, CO; Womack Army Medical Center (A.F., W.C.), Fort Bragg, NC; Evans Army Community Hospital (H.T.), Colorado Springs, CO; and Uniformed Services University of the Health Sciences (A.I.S.), Bethesda MD
| | - Lisa Brenner
- From the Metti Consulting Company (A.M.), Pittsburgh, PA; Defense and Veterans Brain Injury Center (K.S., A.F., R.P.), Silver Spring, MD; 9Line, LLC (K.S.), Tampa, FL; Carolina Headache Institute (A.F.), Durham, NC; Departments of Physical Medicine and Rehabilitation, Psychiatry, and Neurology (L.B.), Anschutz Medical Campus, University of Colorado Aurora; Marcus Institute for Brain Health (L.B.), Aurora; VHA Rocky Mountain Mental Illness Research Education and Clinical Center (L.B.), Denver, CO; Womack Army Medical Center (A.F., W.C.), Fort Bragg, NC; Evans Army Community Hospital (H.T.), Colorado Springs, CO; and Uniformed Services University of the Health Sciences (A.I.S.), Bethesda MD
| | - Wesley Cole
- From the Metti Consulting Company (A.M.), Pittsburgh, PA; Defense and Veterans Brain Injury Center (K.S., A.F., R.P.), Silver Spring, MD; 9Line, LLC (K.S.), Tampa, FL; Carolina Headache Institute (A.F.), Durham, NC; Departments of Physical Medicine and Rehabilitation, Psychiatry, and Neurology (L.B.), Anschutz Medical Campus, University of Colorado Aurora; Marcus Institute for Brain Health (L.B.), Aurora; VHA Rocky Mountain Mental Illness Research Education and Clinical Center (L.B.), Denver, CO; Womack Army Medical Center (A.F., W.C.), Fort Bragg, NC; Evans Army Community Hospital (H.T.), Colorado Springs, CO; and Uniformed Services University of the Health Sciences (A.I.S.), Bethesda MD
| | - Heidi Terrio
- From the Metti Consulting Company (A.M.), Pittsburgh, PA; Defense and Veterans Brain Injury Center (K.S., A.F., R.P.), Silver Spring, MD; 9Line, LLC (K.S.), Tampa, FL; Carolina Headache Institute (A.F.), Durham, NC; Departments of Physical Medicine and Rehabilitation, Psychiatry, and Neurology (L.B.), Anschutz Medical Campus, University of Colorado Aurora; Marcus Institute for Brain Health (L.B.), Aurora; VHA Rocky Mountain Mental Illness Research Education and Clinical Center (L.B.), Denver, CO; Womack Army Medical Center (A.F., W.C.), Fort Bragg, NC; Evans Army Community Hospital (H.T.), Colorado Springs, CO; and Uniformed Services University of the Health Sciences (A.I.S.), Bethesda MD
| | - Ann I Scher
- From the Metti Consulting Company (A.M.), Pittsburgh, PA; Defense and Veterans Brain Injury Center (K.S., A.F., R.P.), Silver Spring, MD; 9Line, LLC (K.S.), Tampa, FL; Carolina Headache Institute (A.F.), Durham, NC; Departments of Physical Medicine and Rehabilitation, Psychiatry, and Neurology (L.B.), Anschutz Medical Campus, University of Colorado Aurora; Marcus Institute for Brain Health (L.B.), Aurora; VHA Rocky Mountain Mental Illness Research Education and Clinical Center (L.B.), Denver, CO; Womack Army Medical Center (A.F., W.C.), Fort Bragg, NC; Evans Army Community Hospital (H.T.), Colorado Springs, CO; and Uniformed Services University of the Health Sciences (A.I.S.), Bethesda MD.
| |
Collapse
|
20
|
Affiliation(s)
- Elizabeth W Loder
- Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Ann I Scher
- Department of Preventive Medicine and Biostatistics, Uniformed Services University, Bethesda, MD, USA
| |
Collapse
|
21
|
Betthauser LM, Adams RS, Hostetter TA, Scher AI, Schwab K, Brenner LA. Characterization of lifetime TBIs in a cohort of recently deployed soldiers: The warrior strong study. Rehabil Psychol 2019; 64:398-406. [PMID: 31368742 DOI: 10.1037/rep0000286] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE To describe and characterize the lifetime history of traumatic brain injury (TBI) among active duty soldiers returning from deployment to Afghanistan or Iraq. METHOD Data were extracted from a larger parent study that was conducted at two large United States Army bases between 2009 and 2014 during Post-Deployment Health Assessment. The sample included 1,060 soldiers who sustained at least one TBI during their lifetime. RESULTS The Ohio State University TBI-Identification Method interview was administered to characterize individuals' total lifetime history of TBI. Soldiers reported sustaining a median of 2 lifetime TBIs. Slightly more than half of the sample without a most recent deployment-related TBI still reported a history of a lifetime TBI (some of which occurred during previous deployments). Most lifetime injuries reported were of mild severity; however, 6% of individuals reported a history of moderate/severe TBI. Blast was the most frequent mechanism associated with recent deployment-related mild TBIs. CONCLUSION Findings suggest that soldiers who screened positive, as well as those who screened negative, for a history of TBI during their recent deployment still endorsed a lifetime history of TBI. Future research is needed to explore the functional impact of multiple TBIs over one's lifetime to help inform screening, assessment, and treatment among military personnel. (PsycINFO Database Record (c) 2019 APA, all rights reserved).
Collapse
Affiliation(s)
- Lisa M Betthauser
- VA Rocky Mountain Mental Illness Research Education and Clinical Center
| | | | | | - Ann I Scher
- Department of Preventive Medicine and Biostatistics
| | | | - Lisa A Brenner
- VA Rocky Mountain Mental Illness Research Education and Clinical Center
| |
Collapse
|
22
|
Ferdosi H, Schwab KA, Metti A, Brenner LA, Terrio H, Pazdan RM, Cole WR, Scher AI. Trajectory of Postconcussive Symptoms 12 Months After Deployment in Soldiers With and Without Mild Traumatic Brain Injury: Warrior Strong Study. Am J Epidemiol 2019; 188:77-86. [PMID: 30203085 DOI: 10.1093/aje/kwy199] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Accepted: 08/27/2018] [Indexed: 12/16/2022] Open
Abstract
We analyzed data from a cohort of recently deployed soldiers from 2 US Army bases, Fort Carson and Fort Bragg (2009 to 2015). Soldiers with and without a recent history of mild traumatic brain injury (mTBI) on deployment were evaluated within days of return and at 3, 6, and 12 months. Those with mTBI were more likely than those without to endorse ≥1 postconcussive symptom as "severe" and/or "very severe" (47% vs. 21%, baseline; adjusted relative risk (RR) = 1.71, 95% confidence interval: 1.51, 1.93, all time points), which remained significant after adjusting for posttraumatic stress disorder (adjusted RR = 1.34, 95% confidence interval: 1.20, 1.50). Prevalence and relative risks for 3 of the most common baseline symptoms remained constant over time: sleep problems (RR = 2.19), forgetfulness (RR = 2.56), and irritability (RR = 2.73). The pattern was slightly different for headache (baseline, RR = 3.44; 12 months, RR = 3.26), due to increased prevalence of headache in those without mTBI. The prevalence of clinically relevant postconcussive symptoms remained relatively constant over 1 year of follow-up, whether or not symptoms were associated with concussion. Service members with recent mTBI reported more symptoms than those without at all time points.
Collapse
Affiliation(s)
- Hamid Ferdosi
- Defense and Veterans Brain Injury Center, TBI Center of Excellence, Silver Spring, Maryland
- Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University, Washington, DC
| | - Karen A Schwab
- Defense and Veterans Brain Injury Center, TBI Center of Excellence, Silver Spring, Maryland
- Uniformed Services University of the Health Sciences, Bethesda, Maryland
| | - Andrea Metti
- Metti Consulting Company, Pittsburgh, Pennsylvania
| | - Lisa A Brenner
- Veterans Health Administration Rocky Mountain Mental Illness Research, Education, and Clinical Center, Denver, Colorado
- Marcus Institute for Brain Health, Anschutz Medical Campus, University of Colorado, Aurora, Colorado
- Department of Psychiatry, Anschutz Medical Campus, University of Colorado, Aurora, Colorado
- Department of Neurology, Anschutz Medical Campus, University of Colorado, Aurora, Colorado
- Department of Physical Medicine and Rehabilitation, Anschutz Medical Campus, University of Colorado, Aurora, Colorado
| | - Heidi Terrio
- Defense and Veterans Brain Injury Center, Evans Army Community Hospital, Colorado Springs, Colorado
| | - Renee M Pazdan
- Defense and Veterans Brain Injury Center, Evans Army Community Hospital, Colorado Springs, Colorado
| | - Wesley R Cole
- Defense and Veterans Brain Injury Center, Fort Bragg, North Carolina
| | - Ann I Scher
- Uniformed Services University of the Health Sciences, Bethesda, Maryland
| |
Collapse
|
23
|
Scher AI, Wang SJ, Katsarava Z, Buse DC, Fanning KM, Adams AM, Lipton RB. Epidemiology of migraine in men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Cephalalgia 2018; 39:296-305. [PMID: 29996667 DOI: 10.1177/0333102418786266] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
OBJECTIVE To assess migraine epidemiology in men by examining gender differences in disease presentation, comorbidities, and prognosis. PATIENTS AND METHODS The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study is a longitudinal survey of US adults with migraine identified by web questionnaire. Data were stratified by gender, collected between September 2012-November 2013, and included sociodemographics, headache features, Migraine Disability Assessment, Migraine Symptom Severity Score, Allodynia Symptom Checklist, and comorbidities. Discrete time hazard models addressed 1-year likelihood of transition from episodic to chronic migraine headache frequency. RESULTS Of the 16,789 migraine respondents, 4294 were men (25.6%). Compared to women, men were slightly older at onset of their headaches (mean 24.1 vs. 22.3 years) and had fewer headache days/month (4.3 vs. 5.3 days), slightly less severe attacks (Migraine Symptom Severity Score, 21.6 vs. 22.6), reduced frequencies of grade IV Migraine Disability Assessment scores (15.7% vs. 24.1%), allodynia (32.6% vs. 49.7%), chronic migraine (6.5% vs. 9.6%, each p < 0.001), and common comorbidities. Men were less likely to report consulting a doctor for their headaches and receiving a migraine diagnosis if they consulted. Men and women with episodic migraine had similar crude 1-year risk of chronic migraine onset. Controlling for known risk factors (i.e. depression, headache frequency, allodynia), men had greater likelihood of chronic migraine onset at 6, 9, and 12 months (each p < 0.05). CONCLUSIONS Findings confirmed gender differences. Men with migraine generally have less severe attacks and disability and are less likely to receive a diagnosis than women with migraine. Prognostic factors may be better understood for women than men.
Collapse
Affiliation(s)
- Ann I Scher
- 1 Department of Preventive Medicine and Biometrics, affiliated with Uniformed Services University of Health Sciences, Bethesda, MD, USA
| | - Shuu-Jiun Wang
- 2 Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.,3 Department of Neurology, Neurological Institute, Taipei Veterans Hospital, Taipei, Taiwan
| | - Zaza Katsarava
- 4 Evangelical Hospital Unna, Department of Neurology, University of Essen, Essen, Germany
| | - Dawn C Buse
- 5 Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.,6 Montefiore Medical Center, Bronx, NY, USA
| | | | | | - Richard B Lipton
- 5 Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.,6 Montefiore Medical Center, Bronx, NY, USA.,9 Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA
| |
Collapse
|
24
|
Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WBF, Adams AM, Buse DC. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 2017; 18:101. [PMID: 28980171 PMCID: PMC5628086 DOI: 10.1186/s10194-017-0787-1] [Citation(s) in RCA: 135] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Accepted: 07/14/2017] [Indexed: 01/03/2023] Open
Abstract
Background Relatively little is known about the stability of a diagnosis of episodic migraine (EM) or chronic migraine (CM) over time. This study examines natural fluctuations in self-reported headache frequency as well as the stability and variation in migraine type among individuals meeting criteria for EM and CM at baseline. Methods The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study was a longitudinal survey of US adults with EM and CM identified by a web-questionnaire. A validated questionnaire was used to classify respondents with EM (<15 headache days/month) or CM (≥15 headache days/month) every three months for a total of five assessments. We described longitudinal persistence of baseline EM and CM classifications. In addition, we modelled longitudinal variation in headache day frequency per month using negative binomial repeated measures regression models (NBRMR). Results Among the 5464 respondents with EM at baseline providing four or five waves of data, 5048 (92.4%) had EM in all waves and 416 (7.6%) had CM in at least one wave. Among 526 respondents with CM at baseline providing four or five waves of data, 140 (26.6%) had CM in every wave and 386 (73.4%) had EM for at least one wave. Individual plots revealed striking within-person variations in headache days per month. The NBRMR model revealed that the rate of headache days increased across waves of observation 19% more per wave for CM compared to EM (rate ratio [RR], 1.19; 95% CI, 1.13–1.26). After adjustment for covariates, the relative difference changed to a 26% increase per wave (RR, 1.26; 95% CI, 1.2–1.33). Conclusions Follow-up at three-month intervals reveals a high level of short-term variability in headache days per month. As a consequence, many individuals cross the CM diagnostic boundary of ≥15 headache days per month.Nearly three quarters of persons with CM at baseline drop below this diagnostic boundary at least once over the course of a year. These findings are of interest in the consideration of headache classification and diagnosis, the design and interpretation of epidemiologic and clinical studies, and clinical management. Electronic supplementary material The online version of this article (doi:10.1186/s10194-017-0787-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
| | - Richard B Lipton
- The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA. .,Montefiore Headache Center; Department of Neurology and Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
| | - Ann I Scher
- Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | | | | | | | - Dawn C Buse
- Montefiore Medical Center, Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
| |
Collapse
|
25
|
Scher AI, Rizzoli PB, Loder EW. Medication overuse headache: An entrenched idea in need of scrutiny. Neurology 2017; 89:1296-1304. [PMID: 28821684 DOI: 10.1212/wnl.0000000000004371] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Accepted: 05/10/2017] [Indexed: 12/31/2022] Open
Abstract
It is a widely accepted idea that medications taken to relieve acute headache pain can paradoxically worsen headache if used too often. This type of secondary headache is referred to as medication overuse headache (MOH); previously used terms include rebound headache and drug-induced headache. In the absence of consensus about the duration of use, amount, and type of medication needed to cause MOH, the default position is conservative. A common recommendation is to limit treatment to no more than 10 or 15 days per month (depending on medication type) to prevent headache frequency progression. Medication withdrawal is often recommended as a first step in treatment of patients with very frequent headaches. Existing evidence, however, does not provide a strong basis for such causal claims about the relationship between medication use and frequent headache. Observational studies linking treatment patterns with headache frequency are by their nature confounded by indication. Medication withdrawal studies have mostly been uncontrolled and often have high dropout rates. Evaluation of this evidence suggests that only a minority of patients required to limit the use of symptomatic medication may benefit from treatment limitation. Similarly, only a minority of patients deemed to be overusing medications may benefit from withdrawal. These findings raise serious questions about the value of withholding or withdrawing symptom-relieving medications from people with frequent headaches solely to prevent or treat MOH. The benefits of doing so are smaller, and the harms larger, than currently recognized. The concept of MOH should be viewed with more skepticism. Until the evidence is better, we should avoid dogmatism about the use of symptomatic medication. Frequent use of symptom-relieving headache medications should be viewed more neutrally, as an indicator of poorly controlled headaches, and not invariably a cause.
Collapse
Affiliation(s)
- Ann I Scher
- From the Department of Preventive Medicine and Biostatistics (A.I.S.), Uniformed Services University, Bethesda, MD; and Department of Neurology (P.B.R., E.W.L.), Brigham and Women's Hospital, Boston, MA.
| | - Paul B Rizzoli
- From the Department of Preventive Medicine and Biostatistics (A.I.S.), Uniformed Services University, Bethesda, MD; and Department of Neurology (P.B.R., E.W.L.), Brigham and Women's Hospital, Boston, MA
| | - Elizabeth W Loder
- From the Department of Preventive Medicine and Biostatistics (A.I.S.), Uniformed Services University, Bethesda, MD; and Department of Neurology (P.B.R., E.W.L.), Brigham and Women's Hospital, Boston, MA
| |
Collapse
|
26
|
Scher AI, Buse DC, Fanning KM, Kelly AM, Franznick DA, Adams AM, Lipton RB. Comorbid pain and migraine chronicity: The Chronic Migraine Epidemiology and Outcomes Study. Neurology 2017; 89:461-468. [PMID: 28679597 PMCID: PMC5539732 DOI: 10.1212/wnl.0000000000004177] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Accepted: 05/10/2017] [Indexed: 01/03/2023] Open
Abstract
Objective: To identify patterns of noncephalic pain comorbidity in people with episodic migraine (EM; <15 headache-days per month) and chronic migraine (CM; ≥15 headache-days per month) and to examine whether the presence of noncephalic pain is an indicator for the 3-month onset or persistence of CM. Methods: Data from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study, a prospective, web-based study with cross-sectional modules embedded in a longitudinal design, were analyzed at baseline and the 3-month follow-up. Relationships between the number of noncephalic pain sites and 3-month onset of CM or persistent CM were assessed. Results: Of 8,908 eligible respondents, 8,139 (91.4%) had EM and 769 (8.6%) had CM at baseline. At 3 months, the incidence of CM among those with baseline EM was 3.4%. When adjusted for demographics and headache-day frequency, the odds of CM onset among those with baseline EM increased by 30% (95% confidence interval [CI] 1.21–1.40, p < 0.001) for each additional noncephalic pain site at baseline. Among those with CM at baseline, 50.1% had persistent CM at the 3-month follow-up. After adjustment for demographics, individuals with CM were 15% (95% CI 1.07–1.25, p < 0.001) more likely to have persistent CM for each additional noncephalic pain site at baseline. Conclusions: These results suggest that noncephalic pain may be a marker for headache chronicity that could be used to identify people with EM at risk of the onset of CM and people with CM at risk of persistent CM.
Collapse
Affiliation(s)
- Ann I Scher
- From the Department of Neurology (D.C.B., R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Montefiore Medical Center (D.C.B., R.B.L.), Bronx, NY; Vedanta Research (K.M.F.), Chapel Hill, NC; Complete Healthcare Communications (A.M.K., D.A.F.), Chadds Ford, PA; Allergan plc (A.M.A.), Irvine, CA. affiliated with the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University of the Health Sciences, Bethesda, MD
| | - Dawn C Buse
- From the Department of Neurology (D.C.B., R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Montefiore Medical Center (D.C.B., R.B.L.), Bronx, NY; Vedanta Research (K.M.F.), Chapel Hill, NC; Complete Healthcare Communications (A.M.K., D.A.F.), Chadds Ford, PA; Allergan plc (A.M.A.), Irvine, CA. affiliated with the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University of the Health Sciences, Bethesda, MD
| | - Kristina M Fanning
- From the Department of Neurology (D.C.B., R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Montefiore Medical Center (D.C.B., R.B.L.), Bronx, NY; Vedanta Research (K.M.F.), Chapel Hill, NC; Complete Healthcare Communications (A.M.K., D.A.F.), Chadds Ford, PA; Allergan plc (A.M.A.), Irvine, CA. affiliated with the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University of the Health Sciences, Bethesda, MD
| | - Amanda M Kelly
- From the Department of Neurology (D.C.B., R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Montefiore Medical Center (D.C.B., R.B.L.), Bronx, NY; Vedanta Research (K.M.F.), Chapel Hill, NC; Complete Healthcare Communications (A.M.K., D.A.F.), Chadds Ford, PA; Allergan plc (A.M.A.), Irvine, CA. affiliated with the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University of the Health Sciences, Bethesda, MD
| | - Dana A Franznick
- From the Department of Neurology (D.C.B., R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Montefiore Medical Center (D.C.B., R.B.L.), Bronx, NY; Vedanta Research (K.M.F.), Chapel Hill, NC; Complete Healthcare Communications (A.M.K., D.A.F.), Chadds Ford, PA; Allergan plc (A.M.A.), Irvine, CA. affiliated with the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University of the Health Sciences, Bethesda, MD
| | - Aubrey M Adams
- From the Department of Neurology (D.C.B., R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Montefiore Medical Center (D.C.B., R.B.L.), Bronx, NY; Vedanta Research (K.M.F.), Chapel Hill, NC; Complete Healthcare Communications (A.M.K., D.A.F.), Chadds Ford, PA; Allergan plc (A.M.A.), Irvine, CA. affiliated with the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University of the Health Sciences, Bethesda, MD
| | - Richard B Lipton
- From the Department of Neurology (D.C.B., R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Montefiore Medical Center (D.C.B., R.B.L.), Bronx, NY; Vedanta Research (K.M.F.), Chapel Hill, NC; Complete Healthcare Communications (A.M.K., D.A.F.), Chadds Ford, PA; Allergan plc (A.M.A.), Irvine, CA. affiliated with the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University of the Health Sciences, Bethesda, MD.
| |
Collapse
|
27
|
Schwab K, Terrio HP, Brenner LA, Pazdan RM, McMillan HP, MacDonald M, Hinds SR, Scher AI. Epidemiology and prognosis of mild traumatic brain injury in returning soldiers. Neurology 2017; 88:1571-1579. [DOI: 10.1212/wnl.0000000000003839] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2016] [Accepted: 01/03/2017] [Indexed: 11/15/2022] Open
Abstract
Objective:Mild traumatic brain injury (mTBI; concussion) is common in returning service members yet limited definitive evidence exists on its prognosis.Methods:Almost 25,000 non–medically evacuated soldiers returning from Afghanistan or Iraq to 2 military bases between 2009 and 2014 were screened for mTBI. We invited a random sample to participate in the present study, oversampling those screening positive, resulting in 557 mTBI cases and 1,010 controls, of whom 366 cases and 599 controls completed 3-month follow-up evaluations. The criterion measure of screened mTBI was the Ohio State University Traumatic Brain Injury Identification Method. Postconcussive symptoms (PCS) were measured at follow-up with the Neurobehavioral Symptom Inventory. Symptoms reported at a severe or very severe level were considered clinically relevant.Results:About half (47%) of soldiers who had sustained an mTBI during this latest deployment reported PCS at 3-month follow-up vs 25% of controls: adjusted odds ratio 2.4 (1.8–3.2). The most commonly reported symptoms (cases vs controls) were sleep problems (30% vs 14%), forgetfulness (21% vs 9%), irritability (17% vs 8%), and headaches (15% vs 5%). mTBI cases were about twice as likely as controls to report receiving rehabilitative services and fair or poor health. Other predictors of PCS included posttraumatic stress, combat exposure, and noncephalic pain. A majority of both cases and controls reported traumatic brain injuries predating this latest deployment.Conclusions:In this nonclinical population of recently deployed soldiers, a substantial proportion of those who had sustained an mTBI were symptomatic 3 months postdeployment. Future studies need to include longer follow-up to measure symptom resolution.Clinicaltrials.gov identifier:NCT01847040.
Collapse
|
28
|
Von Korff M, Scher AI, Helmick C, Carter-Pokras O, Dodick DW, Goulet J, Hamill-Ruth R, LeResche L, Porter L, Tait R, Terman G, Veasley C, Mackey S. United States National Pain Strategy for Population Research: Concepts, Definitions, and Pilot Data. The Journal of Pain 2016; 17:1068-1080. [DOI: 10.1016/j.jpain.2016.06.009] [Citation(s) in RCA: 90] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Revised: 06/14/2016] [Accepted: 06/18/2016] [Indexed: 01/06/2023]
|
29
|
Schwab K, Terrio HP, Brenner LA, Pazdan RM, McMillan HP, MacDonald M, Hinds S, Scher AI. Prognosis of Mild Traumatic Brain Injury in Soldiers Deployed to Afghanistan or Iraq: The Warrior Strong Longitudinal Study. Arch Phys Med Rehabil 2016. [DOI: 10.1016/j.apmr.2016.08.399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
30
|
Lal D, Scher AI. Comment on "Paranasal sinus opacification in headache sufferers: A population-based imaging study (the HUNT study-MRI)". Cephalalgia 2016; 37:507-508. [PMID: 27215545 DOI: 10.1177/0333102416651452] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- Devyani Lal
- 1 Mayo Clinic College of Medicine, Department of Otorhinolaryngology - Head & Neck Surgery, Phoenix, AZ, USA
| | - Ann I Scher
- 2 Uniformed Services University, Bethesda, MD, USA
| |
Collapse
|
31
|
Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A, Lipton RB. Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study. Mayo Clin Proc 2016; 91:S0025-6196(16)00126-9. [PMID: 27132088 DOI: 10.1016/j.mayocp.2016.02.013] [Citation(s) in RCA: 104] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Revised: 02/12/2016] [Accepted: 02/16/2016] [Indexed: 12/18/2022]
Abstract
OBJECTIVE To assess the impact of migraine on family members, activities, and relationships from the perspectives of the person with migraine and his or her spouse/domestic partner. PATIENTS AND METHODS The Chronic Migraine Epidemiology and Outcomes (CaMEO) study is a longitudinal, Web-based study conducted from September 2012 to November 2013. Quota sampling from an online panel identified respondents who met modified International Classification of Headache Disorders, version 3 beta migraine criteria. The Family Burden Module included 24 items covering 6 domains. Findings for respondents with episodic migraine (EM) and chronic migraine (CM) are presented for both the affected individuals and their partners. RESULTS Among 13,064 Family Burden Module respondents (65.7% response rate), there were 4022 migraineur-spouse dyads, including 2275 dyads with children. Burden increased with headache frequency across all 6 domains. People with migraine reported higher family burden due to migraine than did their spouse/partner. Reduced participation in family activities due to migraine was reported 1 or more times a month among 48.2% to 57.4% of migraineurs, depending on headache frequency (days/month). Many (low-frequency to high-frequency EM, 24.4%-40.4%; CM, 43.9%) perceived that their spouse/partner did not believe the severity/impact of their headaches. One-third of migraineurs stated that they worried about long-term financial security for themselves or their family because of their headaches. Many migraineurs felt they would be better parents without headaches (low-frequency to high-frequency EM, 29.9%-58.0%; CM, 71.7%). CONCLUSION This analysis quantified the pervasive burden of migraine on the family, highlighting the impact on family activities and relationships. Not surprisingly, the impact was greatest in families of people with CM.
Collapse
Affiliation(s)
- Dawn C Buse
- Department of Neurology, Albert Einstein College of Medicine, Bronx, NY; Montefiore Medical Center, Bronx, NY.
| | - Ann I Scher
- Department of Preventive Medicine & Biometrics, Affiliated with Uniformed Services University of the Health Sciences, Bethesda, MD
| | | | | | | | | | - Richard B Lipton
- Department of Neurology, Albert Einstein College of Medicine, Bronx, NY; Montefiore Medical Center, Bronx, NY
| |
Collapse
|
32
|
Abstract
BACKGROUND Migraine is comorbid with obesity. Recent research suggests an association between migraine and adipocytokines, proteins that are predominantly secreted from adipose tissue and which participate in energy homeostasis and inflammatory processes. OBJECTIVES In this review, we first briefly discuss the association between migraine and obesity and the importance of adipose tissue as a neuroendocrine organ. We then present a systematic review of the extant literature evaluating circulating levels of adiponectin and leptin in those with migraine. METHODS A search of the PubMed database was conducted using the keywords "migraine," "adiponectin," and "leptin." In addition reference lists of relevant articles were reviewed for possible inclusion. English language studies published between 2005 and 2015 evaluating circulating blood concentration of adiponectin or leptin in those with migraine were included. CONCLUSIONS While the existing data are suggestive that adipokines may be associated with migraine, substantial study design differences and conflicting results limit definitive conclusions. Future research utilizing carefully considered designs and methodology is warranted. In particular careful and systematic characterization of pain states at the time of samples, as well as systematic consideration of demographic (e.g., age, sex) and other vital covariates (e.g., obesity status, lipids) are needed to determine if adipokines play a role in migraine pathophysiology and if any adipokine represents a viable, novel migraine biomarker, or drug target.
Collapse
Affiliation(s)
- B Lee Peterlin
- Johns Hopkins University School of Medicine, Department of Neurology, Baltimore, MD, USA
| | - Simona Sacco
- University of L'Aquila, Department of Applied Clinical Sciences and Biotechnology, Institute of Neurology, L'Aquila, Italy
| | - Claudia Bernecker
- Medical University of Graz, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Graz, Austria.,Medical University of Graz, Department of Blood Group Serology and Transfusion Medicine, Graz, Austria
| | - Ann I Scher
- Uniformed Services University, Bethesda, MD, USA
| |
Collapse
|
33
|
Smallman DP, Webber BJ, Mazuchowski EL, Scher AI, Jones SO, Cantrell JA. Sudden cardiac death associated with physical exertion in the US military, 2005–2010. Br J Sports Med 2015; 50:118-23. [DOI: 10.1136/bjsports-2015-094900] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/31/2015] [Indexed: 12/19/2022]
|
34
|
Rao AS, Scher AI, Vieira RVA, Merikangas KR, Metti AL, Peterlin BL. The Impact of Post-Traumatic Stress Disorder on the Burden of Migraine: Results From the National Comorbidity Survey-Replication. Headache 2015; 55:1323-41. [PMID: 26473981 DOI: 10.1111/head.12698] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/10/2015] [Indexed: 12/01/2022]
Abstract
BACKGROUND Post-traumatic stress disorder (PTSD) has been linked with migraine in prior studies. OBJECTIVE To evaluate the individual and joint burdens of migraine and PTSD in a population-based cohort. METHODS The National Comorbidity Survey-Replication (NCS-R) is a general population study conducted in the United States from February 2001-April 2003. PTSD and migraine were assessed, and four groups defined based on their migraine and PTSD status. The four groups included those with no migraine and no PTSD (controls, n=4535), those with migraine and without PTSD (migraine alone, n=236), those with PTSD and without migraine (PTSD alone, n=244), and those with both migraine and PTSD (mig+PTSD, n=68). Logistic and Poisson regression models were used to assess the association between dichotomous/multilevel outcome variables indicating financial, health, and interpersonal burdens and each migraine/PTSD group. RESULTS Compared to controls, those with Mig+PTSD were more likely to be in the low poverty index (48% vs 41%, AOR 2.16; CI: 1.10, 4.24) and were less likely to be working for pay or profit in the past week (50% vs 68%, AOR 0.42; CI: 0.24, 0.74) but not those with migraine or PTSD alone. Additionally, the number of days where work quality was cut due to physical or mental health or substance abuse in the past month was greater in all groups compared to controls: (1) migraine alone: mean 2.57 (SEM 0.32) vs mean 1.09 (SEM 0.08) days, ARR=2.39; CI: 2.19, 2.62; (2) PTSD alone: mean 2.43 (SEM 0.33) vs mean 1.09 (SEM 0.08) days, ARR=2.09; CI: 1.91, 2.29; (3) mig+PTSD: mean 8.2 (SEM 0.79) vs 1.09 (SEM 0.08) days, ARR 6.79; CI 6.16, 7.49; and was over 2.5-fold greater in those mig+PTSD than migraine alone (mean 8.0 [SEM 0.79] vs 2.6 days [SEM 0.72], ARR 2.77; CI: 2.45, 3.14). The likelihood of having difficulty getting along or maintaining a social life was also increased in all groups relative to controls: (1) migraine alone: 21% vs 5.4%, AOR 4.20; CI: 2.62, 6.74; (2) PTSD alone: 18% vs 5.4%, AOR 3.40; CI: 2.40, 4.82; (3) Mig+PTSD: 39% vs 5.4%, AOR 9.95; CI: 5.72, 17.32, and was 2-fold greater in those with Mig+PTSD as compared to those with migraine alone (AOR 2.32; CI: 1.15, 4.69). CONCLUSIONS These findings support the need for those who treat migraine patients to be aware of the comorbidity with PTSD, as these patients may be particularly prone to adverse financial, health, and interpersonal disease burdens.
Collapse
Affiliation(s)
- Aruna S Rao
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Ann I Scher
- Uniformed Services University, Bethesda, MD, USA
| | - Rebeca V A Vieira
- Department of Psychology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
| | - Kathleen R Merikangas
- National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
| | | | - B Lee Peterlin
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| |
Collapse
|
35
|
|
36
|
Lusk J, Brenner LA, Betthauser LM, Terrio H, Scher AI, Schwab K, Poczwardowski A. A Qualitative Study of Potential Suicide Risk Factors Among Operation Iraqi Freedom/Operation Enduring Freedom Soldiers Returning to the Continental United States (CONUS). J Clin Psychol 2015; 71:843-55. [DOI: 10.1002/jclp.22164] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Jaimie Lusk
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc
- Veterans Integrated Service Network (VISN) 19 Mental Illness Research, Education, and Clinical Center (MIRECC)
- University of Denver, Graduate School of Professional Psychology
| | - Lisa A. Brenner
- Veterans Integrated Service Network (VISN) 19 Mental Illness Research, Education, and Clinical Center (MIRECC)
- University of Colorado Denver, Anschutz Medical Campus, Departments of Psychiatry, Neurology, and Physical Medicine and Rehabilitation
| | - Lisa M. Betthauser
- Veterans Integrated Service Network (VISN) 19 Mental Illness Research, Education, and Clinical Center (MIRECC)
- University of Colorado Denver, Department of Psychology
| | - Heidi Terrio
- Evans Army Community Hospital, University of Colorado Denver, Department of Psychology
- Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury
| | - Ann I. Scher
- Uniformed Services University of the Health Sciences
| | - Karen Schwab
- Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury
- Uniformed Services University of the Health Sciences
| | | |
Collapse
|
37
|
Chai NC, Gelaye B, Tietjen GE, Dash PD, Gower BA, White LW, Ward TN, Scher AI, Peterlin BL. Ictal adipokines are associated with pain severity and treatment response in episodic migraine. Neurology 2015; 84:1409-18. [PMID: 25746563 DOI: 10.1212/wnl.0000000000001443] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2014] [Accepted: 12/18/2014] [Indexed: 12/11/2022] Open
Abstract
OBJECTIVE To evaluate ictal adipokine levels in episodic migraineurs and their association with pain severity and treatment response. METHODS This was a double-blind, placebo-controlled trial evaluating peripheral blood specimens from episodic migraineurs at acute pain onset and 30 to 120 minutes after treatment with sumatriptan/naproxen sodium vs placebo. Total adiponectin (T-ADP), ADP multimers (high molecular weight [HMW], middle molecular weight, and low molecular weight [LMW]), leptin, and resistin levels were evaluated by immunoassays. RESULTS Thirty-four participants (17 responders, 17 nonresponders) were included. In all participants, pretreatment pain severity increased with every quartile increase in both the HMW:T-ADP ratio (coefficient of variation [CV] 0.51; 95% confidence interval [CI]: 0.08, 0.93; p = 0.019) and resistin levels (CV 0.58; 95% CI: 0.21, 0.96; p = 0.002), but was not associated with quartile changes in leptin levels. In responders, T-ADP (CV -0.98; 95% CI: -1.88, -0.08; p = 0.031) and resistin (CV -0.95; 95% CI: -1.83, -0.07; p = 0.034) levels decreased 120 minutes after treatment as compared with pretreatment. In addition, in responders, the HMW:T-ADP ratio (CV -0.04; 95% CI: -0.07, -0.01; p = 0.041) decreased and the LMW:T-ADP ratio (CV 0.04; 95% CI: 0.01, 0.07; p = 0.043) increased at 120 minutes after treatment. In nonresponders, the LMW:T-ADP ratio (CV -0.04; 95% CI: -0.07, -0.01; p = 0.018) decreased 120 minutes after treatment. Leptin was not associated with treatment response. CONCLUSIONS Both pretreatment migraine pain severity and treatment response are associated with changes in adipokine levels. Adipokines represent potential novel migraine biomarkers and drug targets.
Collapse
Affiliation(s)
- Nu Cindy Chai
- From the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD
| | - Bizu Gelaye
- From the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD
| | - Gretchen E Tietjen
- From the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD
| | - Paul D Dash
- From the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD
| | - Barbara A Gower
- From the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD
| | - Linda W White
- From the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD
| | - Thomas N Ward
- From the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD
| | - Ann I Scher
- From the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD
| | - B Lee Peterlin
- From the Department of Neurology (N.C.C., L.W.W., B.L.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Anesthesia (N.C.C.), University of California, San Francisco; Department of Epidemiology (B.G.), Harvard School of Public Health, Boston, MA; Department of Neurology (G.E.T.), University of Toledo, OH; Department of Neurology (P.D.D.), Johns Hopkins Community Physicians, Baltimore, MD; Department of Nutrition Sciences (B.A.G.), University of Alabama at Birmingham; Department of Neurology (T.N.W.), Dartmouth Hitchcock Medical Center, Lebanon, NH; and Uniformed Services University (A.I.S.), Bethesda, MD.
| |
Collapse
|
38
|
Jones SO, Smallman DP, Webber BJ, Mazuchowski EL, Fentanes E, Scher AI, Cantrell JA. ACTIVITIES PERFORMED DURING SUDDEN CARDIAC DEATH ASSOCIATED WITH PHYSICAL EXERTION IN THE UNITED STATES MILITARY. J Am Coll Cardiol 2015. [DOI: 10.1016/s0735-1097(15)60369-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
39
|
Chai NC, Gelaye B, Tietjen GE, Dash PD, Gower BA, White LW, Ward TN, Scher AI, Peterlin BL. EHMTI-0184. Ictal adiponectin levels are modulated by pain severity and treatment response in episodic migraineurs. J Headache Pain 2014. [PMCID: PMC4182173 DOI: 10.1186/1129-2377-15-s1-e25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
40
|
Lipton RB, Serrano D, Adams AM, Buse DC, Scher AI. EHMTI-0169. Trajectories of headache days over one year (5 waves) in chronic and episodic migraineurs participating in the chronic migraine epidemiology and outcomes (cameo) study. J Headache Pain 2014. [PMCID: PMC4178916 DOI: 10.1186/1129-2377-15-s1-d4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
41
|
Chai NC, Scher AI, Moghekar A, Bond DS, Peterlin BL. Obesity and headache: part I--a systematic review of the epidemiology of obesity and headache. Headache 2014; 54:219-34. [PMID: 24512574 DOI: 10.1111/head.12296] [Citation(s) in RCA: 83] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/16/2013] [Indexed: 01/04/2023]
Abstract
Individually, both obesity and headache are conditions associated with a substantial personal and societal impact. Recent data support that obesity is comorbid with headache in general and migraine specifically, as well as with certain secondary headache conditions such as idiopathic intracranial hypertension. In the current manuscript, we first briefly review the epidemiology of obesity and common primary and secondary headache disorders individually. This is followed by a systematic review of the general population data evaluating the association between obesity and headache in general, and then obesity and migraine and tension-type headache disorders. Finally, we briefly discuss the data on the association between obesity and a common secondary headache disorder that is associated with obesity, idiopathic intracranial hypertension. Taken together, these data suggest that it is important for clinicians and patients to be aware of the headache/migraine-obesity association, given that it is potentially modifiable. Hypotheses for mechanisms of the obesity-migraine association and treatment considerations for overweight and obese headache sufferers are discussed in the companion manuscript, as part II of this topic.
Collapse
Affiliation(s)
- Nu Cindy Chai
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | | | | | | | | |
Collapse
|
42
|
Scher AI, Ross GW, Sigurdsson S, Garcia M, Gudmundsson LS, Sveinbjörnsdóttir S, Wagner AK, Gudnason V, Launer LJ. Midlife migraine and late-life parkinsonism: AGES-Reykjavik study. Neurology 2014; 83:1246-52. [PMID: 25230997 DOI: 10.1212/wnl.0000000000000840] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
OBJECTIVE In the present study, we tested the hypothesis that having migraine in middle age is related to late-life parkinsonism and a related disorder, restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED). METHODS The AGES-Reykjavik cohort (born 1907-1935) has been followed since 1967. Headaches were classified based on symptoms assessed in middle age. From 2002 to 2006, 5,764 participants were reexamined to assess symptoms of parkinsonism, diagnosis of Parkinson disease (PD), family history of PD, and RLS/WED. RESULTS Subjects with midlife migraine, particularly migraine with aura (MA), were in later life more likely than others to report parkinsonian symptoms (odds ratio [OR]MA = 3.6 [95% CI 2.7-4.8]) and diagnosed PD (ORMA = 2.5 [95% CI 1.2-5.2]). Women with MA were more likely than others to have a parent (ORMA = 2.26 [95% CI 1.3-4.0]) or sibling (ORMA = 1.78 [95% CI 1.1-2.9]) with PD. Late-life RLS/WED was increased for headache generally. Associations were independent of cardiovascular disease and MRI-evident presumed ischemic lesions. CONCLUSIONS These findings suggest there may be a common vulnerability to, or consequences of, migraine and multiple indicators of parkinsonism. Additional genetic and longitudinal observational studies are needed to identify candidate pathways that may account for the comorbid constellation of symptoms.
Collapse
Affiliation(s)
- Ann I Scher
- From the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University, Bethesda; National Institute on Aging (A.I.S., M.G., L.J.L.), Laboratory of Epidemiology and Population Sciences, Bethesda, MD; Veterans Affairs Pacific Islands Health Care System (G.W.R.), Honolulu; Pacific Health Research & Education Institute (G.W.R.), Honolulu, HI; Icelandic Heart Association (S. Sigurdsson, V.G.), Kopavogur; School of Health Sciences (L.S.G.) and Faculty of Medicine (V.G.), University of Iceland, Reykjavik; Department of Neurology (S. Sveinbjörnsdóttir), Broomfield Hospital, UK; and Department of Physical Medicine and Rehabilitation (A.K.W.), University of Pittsburgh, PA.
| | - G Webster Ross
- From the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University, Bethesda; National Institute on Aging (A.I.S., M.G., L.J.L.), Laboratory of Epidemiology and Population Sciences, Bethesda, MD; Veterans Affairs Pacific Islands Health Care System (G.W.R.), Honolulu; Pacific Health Research & Education Institute (G.W.R.), Honolulu, HI; Icelandic Heart Association (S. Sigurdsson, V.G.), Kopavogur; School of Health Sciences (L.S.G.) and Faculty of Medicine (V.G.), University of Iceland, Reykjavik; Department of Neurology (S. Sveinbjörnsdóttir), Broomfield Hospital, UK; and Department of Physical Medicine and Rehabilitation (A.K.W.), University of Pittsburgh, PA
| | - Sigurdur Sigurdsson
- From the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University, Bethesda; National Institute on Aging (A.I.S., M.G., L.J.L.), Laboratory of Epidemiology and Population Sciences, Bethesda, MD; Veterans Affairs Pacific Islands Health Care System (G.W.R.), Honolulu; Pacific Health Research & Education Institute (G.W.R.), Honolulu, HI; Icelandic Heart Association (S. Sigurdsson, V.G.), Kopavogur; School of Health Sciences (L.S.G.) and Faculty of Medicine (V.G.), University of Iceland, Reykjavik; Department of Neurology (S. Sveinbjörnsdóttir), Broomfield Hospital, UK; and Department of Physical Medicine and Rehabilitation (A.K.W.), University of Pittsburgh, PA
| | - Melissa Garcia
- From the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University, Bethesda; National Institute on Aging (A.I.S., M.G., L.J.L.), Laboratory of Epidemiology and Population Sciences, Bethesda, MD; Veterans Affairs Pacific Islands Health Care System (G.W.R.), Honolulu; Pacific Health Research & Education Institute (G.W.R.), Honolulu, HI; Icelandic Heart Association (S. Sigurdsson, V.G.), Kopavogur; School of Health Sciences (L.S.G.) and Faculty of Medicine (V.G.), University of Iceland, Reykjavik; Department of Neurology (S. Sveinbjörnsdóttir), Broomfield Hospital, UK; and Department of Physical Medicine and Rehabilitation (A.K.W.), University of Pittsburgh, PA
| | - Larus S Gudmundsson
- From the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University, Bethesda; National Institute on Aging (A.I.S., M.G., L.J.L.), Laboratory of Epidemiology and Population Sciences, Bethesda, MD; Veterans Affairs Pacific Islands Health Care System (G.W.R.), Honolulu; Pacific Health Research & Education Institute (G.W.R.), Honolulu, HI; Icelandic Heart Association (S. Sigurdsson, V.G.), Kopavogur; School of Health Sciences (L.S.G.) and Faculty of Medicine (V.G.), University of Iceland, Reykjavik; Department of Neurology (S. Sveinbjörnsdóttir), Broomfield Hospital, UK; and Department of Physical Medicine and Rehabilitation (A.K.W.), University of Pittsburgh, PA
| | - Sigurlaug Sveinbjörnsdóttir
- From the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University, Bethesda; National Institute on Aging (A.I.S., M.G., L.J.L.), Laboratory of Epidemiology and Population Sciences, Bethesda, MD; Veterans Affairs Pacific Islands Health Care System (G.W.R.), Honolulu; Pacific Health Research & Education Institute (G.W.R.), Honolulu, HI; Icelandic Heart Association (S. Sigurdsson, V.G.), Kopavogur; School of Health Sciences (L.S.G.) and Faculty of Medicine (V.G.), University of Iceland, Reykjavik; Department of Neurology (S. Sveinbjörnsdóttir), Broomfield Hospital, UK; and Department of Physical Medicine and Rehabilitation (A.K.W.), University of Pittsburgh, PA
| | - Amy K Wagner
- From the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University, Bethesda; National Institute on Aging (A.I.S., M.G., L.J.L.), Laboratory of Epidemiology and Population Sciences, Bethesda, MD; Veterans Affairs Pacific Islands Health Care System (G.W.R.), Honolulu; Pacific Health Research & Education Institute (G.W.R.), Honolulu, HI; Icelandic Heart Association (S. Sigurdsson, V.G.), Kopavogur; School of Health Sciences (L.S.G.) and Faculty of Medicine (V.G.), University of Iceland, Reykjavik; Department of Neurology (S. Sveinbjörnsdóttir), Broomfield Hospital, UK; and Department of Physical Medicine and Rehabilitation (A.K.W.), University of Pittsburgh, PA
| | - Vilmundur Gudnason
- From the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University, Bethesda; National Institute on Aging (A.I.S., M.G., L.J.L.), Laboratory of Epidemiology and Population Sciences, Bethesda, MD; Veterans Affairs Pacific Islands Health Care System (G.W.R.), Honolulu; Pacific Health Research & Education Institute (G.W.R.), Honolulu, HI; Icelandic Heart Association (S. Sigurdsson, V.G.), Kopavogur; School of Health Sciences (L.S.G.) and Faculty of Medicine (V.G.), University of Iceland, Reykjavik; Department of Neurology (S. Sveinbjörnsdóttir), Broomfield Hospital, UK; and Department of Physical Medicine and Rehabilitation (A.K.W.), University of Pittsburgh, PA
| | - Lenore J Launer
- From the Department of Preventive Medicine and Biometrics (A.I.S.), Uniformed Services University, Bethesda; National Institute on Aging (A.I.S., M.G., L.J.L.), Laboratory of Epidemiology and Population Sciences, Bethesda, MD; Veterans Affairs Pacific Islands Health Care System (G.W.R.), Honolulu; Pacific Health Research & Education Institute (G.W.R.), Honolulu, HI; Icelandic Heart Association (S. Sigurdsson, V.G.), Kopavogur; School of Health Sciences (L.S.G.) and Faculty of Medicine (V.G.), University of Iceland, Reykjavik; Department of Neurology (S. Sveinbjörnsdóttir), Broomfield Hospital, UK; and Department of Physical Medicine and Rehabilitation (A.K.W.), University of Pittsburgh, PA
| |
Collapse
|
43
|
Cha NC, Scher AI, Moghekar A, Bond DS, Peterlin BL. Perceived body weight status of youngsters interferes with headache in obese and non-obese subjects: a response. Headache 2014; 54:1063-5. [PMID: 24916594 DOI: 10.1111/head.12377] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Nu Cindy Cha
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | | | | | | | | |
Collapse
|
44
|
Abstract
Obesity and headache are both associated with a substantial personal and societal impact, and epidemiologic studies have consistently identified a positive association between obesity and headache in general, as well as obesity and migraine specifically (see part I). In the current manuscript, we will discuss the potential mechanisms for the migraine-obesity association, with a focus on the central and peripheral pathophysiological pathways which overlap between migraine and those modulating the drive to feed. We then discuss surgical, behavioral, and pharmacological treatment considerations for overweight and obese migraineurs as well as for those with idiopathic intracranial hypertension. We close by briefly discussing where future research may be headed in light of this data.
Collapse
Affiliation(s)
- Nu Cindy Chai
- School of Medicine - Neurology, Johns Hopkins University, Baltimore, MD, USA
| | | | | | | | | |
Collapse
|
45
|
Stovner LJ, Al Jumah M, Birbeck GL, Gururaj G, Jensen R, Katsarava Z, Queiroz LP, Scher AI, Tekle-Haimanot R, Wang SJ, Steiner TJ. The methodology of population surveys of headache prevalence, burden and cost: principles and recommendations from the Global Campaign against Headache. J Headache Pain 2014; 15:5. [PMID: 24467862 PMCID: PMC3907133 DOI: 10.1186/1129-2377-15-5] [Citation(s) in RCA: 104] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2013] [Accepted: 01/02/2014] [Indexed: 11/10/2022] Open
Abstract
The global burden of headache is very large, but knowledge of it is far from complete and needs still to be gathered. Published population-based studies have used variable methodology, which has influenced findings and made comparisons difficult. Among the initiatives of the Global Campaign against Headache to improve and standardize methods in use for cross-sectional studies, the most important is the production of consensus-based methodological guidelines. This report describes the development of detailed principles and recommendations. For this purpose we brought together an expert consensus group to include experience and competence in headache epidemiology and/or epidemiology in general and drawn from all six WHO world regions. The recommendations presented are for anyone, of whatever background, with interests in designing, performing, understanding or assessing studies that measure or describe the burden of headache in populations. While aimed principally at researchers whose main interests are in the field of headache, they should also be useful, at least in parts, to those who are expert in public health or epidemiology and wish to extend their interest into the field of headache disorders. Most of all, these recommendations seek to encourage collaborations between specialists in headache disorders and epidemiologists. The focus is on migraine, tension-type headache and medication-overuse headache, but they are not intended to be exclusive to these. The burdens arising from secondary headaches are, in the majority of cases, more correctly attributed to the underlying disorders. Nevertheless, the principles outlined here are relevant for epidemiological studies on secondary headaches, provided that adequate definitions can be not only given but also applied in questionnaires or other survey instruments.
Collapse
Affiliation(s)
- Lars Jacob Stovner
- Norwegian National Headache Centre, Norwegian University of Science and Technology, and St, Olavs University Hospital, Trondheim, Norway.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Steiner TJ, Gururaj G, Andrée C, Katsarava Z, Ayzenberg I, Yu SY, Al Jumah M, Tekle-Haimanot R, Birbeck GL, Herekar A, Linde M, Mbewe E, Manandhar K, Risal A, Jensen R, Queiroz LP, Scher AI, Wang SJ, Stovner LJ. Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaire. J Headache Pain 2014; 15:3. [PMID: 24400999 PMCID: PMC3906903 DOI: 10.1186/1129-2377-15-3] [Citation(s) in RCA: 110] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2013] [Accepted: 01/02/2014] [Indexed: 11/10/2022] Open
Abstract
The global burden of headache is very large, but knowledge of it is far from complete and needs still to be gathered. Published population-based studies have used variable methodology, which has influenced findings and made comparisons difficult. The Global Campaign against Headache is undertaking initiatives to improve and standardize methods in use for cross-sectional studies. One requirement is for a survey instrument with proven cross-cultural validity. This report describes the development of such an instrument. Two of the authors developed the initial version, which was used with adaptations in population-based studies in China, Ethiopia, India, Nepal, Pakistan, Russia, Saudi Arabia, Zambia and 10 countries in the European Union. The resultant evolution of this instrument was reviewed by an expert consensus group drawn from all world regions. The final output was the Headache-Attributed Restriction, Disability, Social Handicap and Impaired Participation (HARDSHIP) questionnaire, designed for application by trained lay interviewers. HARDSHIP is a modular instrument incorporating demographic enquiry, diagnostic questions based on ICHD-3 beta criteria, and enquiries into each of the following as components of headache-attributed burden: symptom burden; health-care utilization; disability and productive time losses; impact on education, career and earnings; perception of control; interictal burden; overall individual burden; effects on relationships and family dynamics; effects on others, including household partner and children; quality of life; wellbeing; obesity as a comorbidity. HARDSHIP already has demonstrated validity and acceptability in multiple languages and cultures. Modules may be included or not, and others (eg, on additional comorbidities) added, according to the purpose of the study and resources (especially time) available.
Collapse
Affiliation(s)
- Timothy J Steiner
- Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Steiner TJ, Stovner LJ, Al Jumah M, Birbeck GL, Gururaj G, Jensen R, Katsarava Z, Queiroz LP, Scher AI, Tekle-Haimanot R, Wang SJ, Martelletti P, Dua T, Chatterji S. Improving quality in population surveys of headache prevalence, burden and cost: key methodological considerations. J Headache Pain 2013; 14:87. [PMID: 24160915 PMCID: PMC4231353 DOI: 10.1186/1129-2377-14-87] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2013] [Accepted: 10/14/2013] [Indexed: 11/29/2022] Open
Abstract
Population-based studies of headache disorders are important. They inform needs assessment and underpin service policy for a set of disorders that are a public-health priority. On the one hand, our knowledge of the global burden of headache is incomplete, with major geographical gaps; on the other, methodological differences and variable quality are notable among published studies of headache prevalence, burden and cost. The purpose here was to start the process of developing standardized and better methodology in these studies. An expert consensus group was assembled to identify the key methodological issues, and areas where studies might fail. Members had competence and practical experience in headache epidemiology or epidemiology in general, and were drawn from all WHO world regions. We reviewed the relevant literature, and supplemented the knowledge gathered from this exercise with experience gained from recent Global Campaign population-based studies, not all yet published. We extracted methodological themes and identified issues within them that were of key importance. We found wide variations in methodology. The themes within which methodological shortcomings had adverse impact on quality were the following: study design; selection and/or definition of population of interest; sampling and bias avoidance; sample size estimation; access to selected subjects (managing and reporting non-participation); case definition (including diagnosis and timeframe); case ascertainment (including diagnostic validation of questionnaires); burden estimation; reporting (methods and results). These are discussed.
Collapse
Affiliation(s)
- Timothy J Steiner
- Norwegian National Headache Centre, Norwegian University of Science and Technology, and St Olavs University Hospital, Trondheim, Norway
- Department of Neuroscience, Imperial College London, London, UK
| | - Lars Jacob Stovner
- Norwegian National Headache Centre, Norwegian University of Science and Technology, and St Olavs University Hospital, Trondheim, Norway
| | - Mohammed Al Jumah
- King Saud Bin Abdul-Aziz University for Health Sciences, Riyadh, Saudi Arabia
| | - Gretchen L Birbeck
- Department of Neurology, University of Rochester, Rochester, NY, USA
- Chikankata Hospital, Mazabuka, Zambia
| | - Gopalakrishna Gururaj
- Department of Epidemiology, Centre for Public Health, National Institute of Mental Health and Neuro Sciences, Bangalore, India
| | - Rigmor Jensen
- Danish Headache Centre, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark
| | - Zaza Katsarava
- Evangelical Hospital, Unna, Germany
- Department of Neurology, University of Duisburg-Essen, Essen, Germany
| | - Luiz Paulo Queiroz
- Department of Neurology, University Hospital, Federal University of Santa Catarina, Florianopolis, Brazil
| | - Ann I Scher
- Uniformed Services University, Bethesda, MD, USA
| | - Redda Tekle-Haimanot
- School of Medicine, Department of Neurology, Addis Ababa University, Addis Ababa, Ethiopia
| | - Shuu-Jiun Wang
- The Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan
- Department of Neurology, Brain Research Center and Institute of Brain Science, National Yang-Ming University of School of Medicine, Taipei, Taiwan
| | - Paolo Martelletti
- Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy
| | - Tarun Dua
- Department of Mental Health and Substance Abuse, World Health Organization, Geneva, Switzerland
| | - Somnath Chatterji
- Department of Health Statistics and Informatics, World Health Organization, Geneva, Switzerland
| |
Collapse
|
48
|
Abstract
For decades, the question of social selection vs social causation has been raised by public health researchers and social scientists to explain the association between socioeconomic factors and mood disorders.(1,2) The social selection or "downward drift" theory postulates that the disease itself limits an individual's educational and occupational achievements, leading to a lower socioeconomic status (SES). In contrast, the social causation hypothesis suggests that factors associated with low SES (e.g., stressful life events, poor health care access) increase the likelihood of disease onset or prolonged disease duration.(3,4) Simply stated, the end result of each hypothesis is as follows:
Collapse
Affiliation(s)
- B Lee Peterlin
- From the Department of Neurology (B.L.P.), Johns Hopkins University School of Medicine, Baltimore; and Department of Preventive Medicine Biometrics (A.I.S.), Uniformed Services University, Bethesda, MD
| | | |
Collapse
|
49
|
Scher AI, Monteith TS. Epidemiology and classification of post-traumatic headache: what do we know and how do we move forward? Comment on Lucas et al., "Prevalence and characterization of headache following mild TBI". Cephalalgia 2013; 34:83-5. [PMID: 23928363 DOI: 10.1177/0333102413499644] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Ann I Scher
- Preventive Medicine and Biometrics, Uniformed Services University, MD, USA
| | | |
Collapse
|
50
|
Gudmundsson LS, Scher AI, Sigurdsson S, Geerlings MI, Vidal JS, Eiriksdottir G, Garcia MI, Harris TB, Kjartansson O, Aspelund T, van Buchem MA, Gudnason V, Launer LJ. Migraine, depression, and brain volume: the AGES-Reykjavik Study. Neurology 2013; 80:2138-44. [PMID: 23700334 DOI: 10.1212/wnl.0b013e318295d69e] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
OBJECTIVE To examine the joint association of migraine headache and major depressive disorder on brain volume in older persons without dementia. METHODS Participants (n = 4,296, 58% women) from the population-based Age, Gene/Environment Susceptibility-Reykjavik Study were assessed for migraine headache in 1967-1991 (age 51 years [range 33-65]) according to modified International Classification of Headache Disorders-II criteria. In 2002-2006 (age 76 years [range 66-96]), lifetime history of major depressive disorder (depression) was diagnosed according to DSM-IV criteria, and full-brain MRI was acquired, which was computer postprocessed into total brain volume (TBV) (gray matter [GM], white matter [WM], white matter hyperintensities) and CSF volume for each study subject. We compared brain tissue volumes by headache categories with or without depression using linear regression, adjusting for intracranial volume and other factors. RESULTS Compared with the reference group (no headache, no depression) TBV and WM and GM volumes were smaller in those with both migraine and depression (TBV -19.2 mL, 95% confidence interval [CI] -35.3, -3.1, p = 0.02; WM -12.8 mL, CI -21.3, -4.3, p = 0.003; GM -13.0 mL, CI -26.0, 0.1, p = 0.05) but not for those with migraine alone (TBV 0.4 mL, WM 0.2 mL, GM 0.6 mL) or depression alone (TBV -3.9 mL, WM -0.9 mL, GM -2.9 mL). CONCLUSIONS Reporting both migraine and major depressive disorder was associated with smaller brain tissue volumes than having one or neither of these conditions. Migraineurs with depression may represent a distinct clinical phenotype with different long-term sequelae. Nonetheless, the number of subjects in the current study is relatively small and these findings need to be confirmed in future studies.
Collapse
Affiliation(s)
- Larus S Gudmundsson
- Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, National Institute on Aging, Bethesda, MD, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|